KR101891049B1 - Immunodiagnostic cartridge - Google Patents

Abstract

According to an embodiment of the present invention, an immunodiagnostic cartridge comprises: a transfer pad in which a plurality of antigens and fluids move in a first direction; a first absorbent pad in contact with the transfer pad to absorb the fluid to allow the fluid to move in a first direction on the transfer pad; a second absorbent pad located on a first side in a second direction of the transfer pad, and in contact with the transfer pad; and a cleaning vessel located in a region adjacent to a second side in a second direction of the transfer pad, and accommodating a cleaning liquid. A test line is formed on the transfer pad, the fluid is absorbed into one of the first absorbent pad and a second absorbent pad after passing the test line, and the cleaning liquid is absorbed into one of the first absorbent pad and a second absorbent pad after passing the test line.

Description

{Immunodiagnostic cartridge}

An embodiment relates to an immunodiagnostic cartridge.

Immunodiagnosis refers to a system for diagnosing a disease by detecting a biomarker produced by a disease using the principle of specifically binding antigen-antibody reaction.

The immunodiagnosis is the largest part of the in vitro diagnostic market.

Point of care testing (POCT) of the in vitro diagnostic market includes a cartridge and a diagnostic device, and the cartridge may be composed of a membrane-based test strip and a housing surrounding the test strip.

The on-site diagnosis can be performed and interpreted quickly by a doctor using whole blood, urine, or saliva, and is used for diagnosis of various diseases.

Conventional immunodiagnosis can be configured in a sandwich manner. In the sandwich method, for example, a sample is put in a state in which an antibody is fixed on a membrane by a test line, and a marker that specifically binds to the sample is introduced to bind the sample antigen and the marker to the immobilized antibody. It is a way to measure change. A fluorescent substance is mainly used as a marker, and a light is generated by a fluorescent substance to perform a diagnosis.

In the case of the sandwich method, an antigen has to have two or more epitopes, and thus there is a problem in detecting an antigen having a small molecular weight.

Competition has been developed as a method for detecting small molecular weight antigens. Competitive approach is to quantitatively measure biomarkers by competition between two antigens for the same binding site of antibody.

For example, a sample is injected while the antibody is immobilized on the membrane with a test line, and the change of the test line is measured by binding a marker to the same antigen as the sample.

This competitive method of field diagnosis requires a method to improve the diagnostic accuracy of the disease.

In addition, various diseases such as heart disease, pregnancy diagnosis and infectious disease diagnosis are being diagnosed by the field diagnosis method.

Recently, there has been a demand for diagnosis of osteoporosis and osteoporotic fracture, which are typical aging diseases.

Conventionally, the diagnosis of osteoporosis is made through physical methods such as X-ray imaging. However, this method requires a large-scale diagnostic apparatus, has a problem of safety due to the use of X-rays, It is difficult to accurately predict the risk of osteoporotic fracture only by the bone mineral density value.

In order to overcome these drawbacks, there is a need for a field diagnostic device capable of diagnosing the risk of osteoporotic fracture.

Embodiments provide an immunodiagnostic cartridge capable of improving diagnostic accuracy.

An immunodiagnostic cartridge according to an embodiment includes: a deployment pad in which a plurality of antigens and fluids move in a first direction; A first absorbent pad in contact with the deployment pad to absorb the fluid to cause the fluid to move in a first direction on the deployment pad; A second absorbing pad located on a first side of the deployment pad in a second direction and in contact with the deployment pad; And a cleaning vessel located in a region adjacent to a second side in the second direction of the deployment pad, the cleaning vessel receiving a cleaning liquid, wherein a test line is formed on the development pad, 1 absorption pad and the second absorption pad, and the cleaning liquid can be absorbed into the first absorption pad and / or the second absorption pad through the test line.

An immunodiagnostic cartridge according to an embodiment includes: a deployment pad in which a plurality of antigens and fluids move in a first direction; A first absorbent pad in contact with the deployment pad to absorb the fluid to cause the fluid to move in a first direction on the deployment pad; And a cleaning vessel located above the deployment pad, the cleaning vessel receiving a cleaning liquid, wherein a test line is formed on the development pad, the fluid is absorbed into the first absorption pad through the test line, Any one of the plurality of antigens is introduced into the development pad after being contacted with the test line and absorbed into the first absorption pad.

The immunodiagnostic cartridge according to the embodiment can improve the diagnostic accuracy by forming the washing liquid through the test line.

1 is a view showing an immunoassay POCT 1 according to the first embodiment.
2 is a block diagram showing the POCT 1 for immunological diagnosis according to the first embodiment.
3 is a view showing a cartridge according to the first embodiment.
FIG. 4 is a view showing movement of a specimen and a competitor at a first time point in the cartridge according to the first embodiment. FIG.
FIG. 5 is a diagram showing movement of a specimen and a competitor at a second time point in the cartridge according to the first embodiment. FIG.
FIG. 6 is a diagram showing movement of a specimen and a competitor at a third time point in the cartridge according to the first embodiment. FIG.
FIG. 7 is a diagram showing movement of a specimen and a competitor at a fourth time point in the cartridge according to the first embodiment. FIG.
8 is a view showing a cartridge according to the second embodiment.
9 is a view showing a cartridge according to the third embodiment.
10 is a view showing a cartridge according to the fourth embodiment.
11 is a view showing a cartridge according to a fifth embodiment.
12 is a view showing a state in which the reaction of the cartridge according to the fifth embodiment is completed.
13 is a view showing a cartridge according to a sixth embodiment.
14 is a view showing a state in which the reaction of the cartridge according to the sixth embodiment is completed.
15 is a view showing a cartridge according to a seventh embodiment.
16 is a view showing a state in which the reaction of the cartridge according to the seventh embodiment is completed.
17 is a view showing a cartridge according to an eighth embodiment.
18 is a view showing movement of a sample and a sensing derivative at a first time point in the cartridge according to the eighth embodiment.
19 is a diagram showing the movement of a sample and a sensing derivative at a second time point in the cartridge according to the eighth embodiment.
20 is a view showing movement of a sample and a sensing derivative at a third time point in the cartridge according to the eighth embodiment.
21 is a view showing a cartridge according to the ninth embodiment.
FIG. 22 is a view showing the solution insertion of the cartridge according to the ninth embodiment. FIG.
23 is a view showing a cartridge according to the tenth embodiment.
24 is a view showing a cartridge into which the cleaning solution according to the tenth embodiment is introduced.
25 is a view showing the cartridge after the cleaning solution according to the tenth embodiment is inserted.
26 is a view showing a cartridge according to the eleventh embodiment.
27 is a view showing a cartridge according to a twelfth embodiment.
28 is a view showing a cartridge before the cleaning solution according to the twelfth embodiment is introduced.
29 is a view showing the cartridge after the cleaning solution according to the twelfth embodiment is charged.
30 is a view showing a cartridge according to the thirteenth embodiment.
31 is a view showing the cartridge according to the thirteenth embodiment before the cleaning liquid is introduced.
32 is a view showing the cartridge according to the thirteenth embodiment after the cleaning liquid is introduced.
33 is a view showing a cartridge according to the fourteenth embodiment.

Hereinafter, specific embodiments of the present invention will be described in detail with reference to the drawings. It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the inventive concept. Other embodiments falling within the scope of the inventive concept may readily be suggested, but are also considered to be within the scope of the present invention.

The same reference numerals are used to designate the same components in the same reference numerals in the drawings of the embodiments.

An immunoassay cartridge according to an embodiment includes: a development pad in which a fluid moves in a first direction; And an absorbent pad in contact with the deployment pad to absorb the fluid to cause the fluid to move in a first direction on the deployment pad, wherein the deployment pad includes a first region, a second region, and a third region , A sample containing a fluid and a plurality of antigens is introduced into the first region, a plurality of competitors are introduced into the second region, the third region is a region adjacent to the absorbent pad, A plurality of antigens or a plurality of antibodies each of which binds to a plurality of competitors, wherein the plurality of competitors are capable of detecting an antigen of the plurality of antigens after reaching the test line do.

The antibody may selectively bind to any one of the antigen and the competitor.

The competitor may move to the absorbent pad through the third region when the antibody binds to the antigen.

The antigen moves at a first speed in the test line direction and the competitor moves at a second speed in the test line direction and the first speed may be faster than the second speed.

The competitor can move in the direction of the test line by the fluid.

The fluid moves at a third speed in the test line direction and the deviation of the second speed and the third speed may be less than the deviation of the first speed and the third speed.

Each of the fluid, the antigen, and the competitor occupying an area on the development pad from a minimum development point to a maximum development point at a specific time point, and a maximum development point of the antigen and a maximum development point of the competitor at a first time point The difference between the maximum deployment point of the antigen and the maximum deployment point of the competitor at a second point in time after the first point of view is different by a second distance, and the first distance may be smaller than the second distance.

The antigen and the competitor may have a corresponding antigenic determinant.

The competitor may have a higher molecular weight than the antigen.

The competitor may comprise an antigenic derivative and a marker.

The competitor's marker is linked to a protein, and the marker can be linked to the antigenic derivative by the protein.

The second region may be a side surface of the third region in a second direction, and the second direction may be a direction perpendicular to the first direction.

The plurality of competitors may further include a container in which the plurality of competitors are stored, and a plurality of competitors stored in the container may be introduced into the third region in the second direction through the second region.

A plurality of competitors stored in the container can be introduced into the third region through the second region after the antigen of any one of the plurality of antigens reaches the test line.

The area of the third area where the test line is located may have a different development speed from the area of the third area where the test line is not located.

The development speed of the area of the third area where the test line is located may have a slower development speed than the area of the third area where the test line is not located.

And a solution storage unit for applying a solution between the first region and the second region.

The movement of the sample introduced into the first region to the second region by the solution applied to the development pad from the solution storage portion can be restricted.

The solution from the solution reservoir may be injected into the deployment pad after a predetermined time elapses from the introduction of the specimen into the first region.

The solution from the solution reservoir can be introduced in the second direction.

The hydrogen ion concentration index of the development pad can be adjusted by the solution from the solution reservoir.

A sandwich test line consisting of a plurality of sandwich antibodies is located in the region of the third region adjacent to the test line, the sandwich antibody specifically binds to the sandwich antigen in the sample, and the sandwich antigen binds to the test line And may not bind to the plurality of antibodies.

A sandwich marker that binds to the sandwich antigen may be introduced into the second region.

The test line and the sandwich test line may be positioned parallel to each other along the second direction.

The development pad may include one side region and another side region that are divided along the first direction, the test line may be located in the one side region, and the sandwich test line may be located in the other side region.

And a boundary film positioned at a boundary between the one side region and the other side region of the second region and the third region.

Wherein the antigen further comprises a fourth region located between the first region and the second region, wherein the fourth region comprises an LDL (low-density lipoprotein) antigen and a high-density lipoprotein (HDL) An antibody that specifically binds to an LDL antigen may be located.

The dissolution solution for dissolving the specimen may be located in the fourth region.

Said competitor may comprise a Sphingosine-1-phosphate (S1P) derivative.

The antigen may comprise S1P (Sphingosine-1-phosphate).

The immunoassay POCT according to an embodiment includes the immunological diagnostic cartridge; And a detection unit for detecting light in the third area of the immunity diagnostic cartridge.

A cartridge for diagnosing osteoporotic fracture risk according to an embodiment includes: a deployment pad in which fluid moves in a first direction; And an absorbent pad in contact with the deployment pad to absorb the fluid to cause the fluid to move in a first direction on the deployment pad, wherein the deployment pad includes a first region, a second region, and a third region , A sample containing a fluid and a plurality of antigens is introduced into the first region, a plurality of S1P derivatives each having a label attached thereto are introduced into the second region, and the third region is a region adjacent to the absorption pad A test line comprising a plurality of antibodies each binding to the plurality of antigens or a plurality of S1P derivatives is located in the third region, and wherein the plurality of S1P derivatives bind to any one of the plurality of antigens on the test line Reach the test line.

A POCT for diagnosing osteoporotic fracture risk according to an embodiment includes: a cartridge for diagnosing osteoporotic fracture risk; A detector for detecting light in the third region of the cartridge for diagnosing osteoporotic fracture risk; And a controller for analyzing the light detected through the detector to determine the risk of osteoporotic fracture.

An immunodiagnostic cartridge according to an embodiment includes: a deployment pad in which a plurality of antigens and fluids move in a first direction; A first absorbent pad in contact with the deployment pad to absorb the fluid to cause the fluid to move in a first direction on the deployment pad; A second absorbing pad located on a first side of the deployment pad in a second direction and in contact with the deployment pad; And a cleaning vessel located in a region adjacent to a second side in the second direction of the deployment pad, the cleaning vessel receiving a cleaning liquid, wherein a test line is formed on the development pad, 1 absorption pad and the second absorption pad, and the cleaning liquid can be absorbed into the first absorption pad and / or the second absorption pad through the test line.

Wherein the development pad comprises a first region and a second region, wherein a sample containing a plurality of antigens and fluids is introduced into the first region, the test line is located in the second region, The first end may be adjacent to the first side, and the second end of the test line may be adjacent to the second side.

The distance between the first end of the test line and the first region may be less than the distance between the second absorbent pad and the first region.

The distance between the second end of the test line and the first region may be less than the distance between the first absorbent pad and the first region.

The test lines may extend diagonally on the deployment pads.

After the antigen of any one of the plurality of antigens meets the test line, the wash liquid may be introduced into the development pad.

All of the fluid and wash fluid absorbed in the first or second absorbent pad may be fluid and wash fluid past the test line.

The first absorbing pad and the second absorbing pad may be integrally formed.

The boundary between the first region and the second region may be parallel to the test line.

The boundary between the deployment pad and the first absorbent pad may be parallel to the test line.

And a third region located between the first region and the second region, wherein a competitor is introduced into the third region, and a boundary between the third region and the second region may be parallel to the test line .

Said deployment pad. A first absorbent pad. And a housing for receiving the second absorbent pad and the cleaning container, wherein a hollow is formed in the housing to introduce a sample from the outside into the development pad, and the long axis of the hollow can be parallel to the test line.

An immunodiagnostic cartridge according to an embodiment includes: a deployment pad in which a plurality of antigens and fluids move in a first direction; A first absorbent pad in contact with the deployment pad to absorb the fluid to cause the fluid to move in a first direction on the deployment pad; And a cleaning vessel located above the deployment pad, the cleaning vessel receiving a cleaning liquid, wherein a test line is formed on the development pad, the fluid is absorbed into the first absorption pad through the test line, Any one of the plurality of antigens is introduced into the development pad after being contacted with the test line and absorbed into the first absorption pad.

The first absorbent pad may have an absorbent capacity capable of absorbing both the fluid and the washing liquid.

And a second absorbent pad adjacent to the first absorbent pad, wherein the second absorbent pad may have greater absorbency than the first absorbent pad.

The second absorbent pad absorbs moisture absorbed by the first absorbent pad, and the first absorbent pad can absorb moisture transferred from the development pad.

The first absorbent pad absorbs the fluid, and the second absorbent pad absorbs the fluid of the first absorbent pad, after which the first absorbent pad absorbs the wash fluid.

The absorption capacity of the first absorption pad can be increased by the second absorption pad after absorbing the fluid.

And a blocking pad between the first absorbing pad and the second absorbing pad, and the second absorbing pad may include a protrusion protruding in the direction of the test line from the first absorbing pad.

The projecting portion of the second absorbent pad may contact the development pad by an external force to absorb the cleaning liquid.

The projection of the second absorbent pad can contact the deployment pad after the fluid reaches the first absorbent pad.

1 is a view showing an immunoassay POCT 1 according to the first embodiment.

Referring to FIG. 1, the immunoassay POCT 1 according to the first embodiment may include a diagnostic apparatus 100 and a cartridge 1000.

The diagnostic device 100 may be a diagnostic device for immunodiagnosis, and the cartridge 1000 may be an immunodiagnostic cartridge.

The diagnostic device 100 may analyze a specific component of the specimen injected into the cartridge 1000. [ The diagnostic apparatus 100 may analyze whether a specific antigen is present in the specimen injected into the cartridge 1000. The diagnostic apparatus 100 may analyze the concentration of the specific antigen of the specimen injected into the cartridge 1000. The diagnostic apparatus 100 may analyze the Sphingosine-1-phosphate (S1P) concentration of the specimen injected into the cartridge 1000. The diagnostic apparatus 100 may analyze the risk of osteoporotic fracture using the specimen injected into the cartridge 1000. The diagnostic apparatus 100 can measure the S1P (Sphingosine-1-phosphate) concentration of the specimen injected into the cartridge 1000 to analyze the risk of osteoporotic fracture of the subject.

The cartridge 1000 can be injected with a specimen. Blood of the subject can be injected into the cartridge 1000. The antigen of the specimen injected into the cartridge 1000 may be fixed to a part of the area of the cartridge 1000 through an immune reaction. The diagnostic apparatus 100 may measure the concentration of the antigen in the specimen by measuring whether the antigen is immobilized in the cartridge 1000.

The cartridge 1000 may be inserted into the diagnostic device 100. The cartridge 1000 may be inserted into the diagnostic apparatus 100 after the specimen is injected. Alternatively, the cartridge 1000 may be inserted into the diagnostic apparatus 100 without injecting a sample, and the sample 1000 may be injected after the cartridge 1000 is inserted into the diagnostic apparatus 100.

2 is a block diagram showing the POCT 1 for immunological diagnosis according to the first embodiment.

Referring to FIG. 2, the immunoassay POCT 1 according to the first embodiment may include the diagnostic apparatus 100 and the cartridge 1000.

The diagnostic apparatus 100 may include a control unit 110 and a measurement unit 130.

The control unit 110 may control the configuration of the diagnostic device 100. FIG. The control unit 110 may control the operation of the cartridge 1000. [ The controller 110 may control a part of the configuration of the diagnostic apparatus 100 so that the cartridge 1000 operates. The control unit 110 may control the measurement unit 130.

The measuring unit 130 may be connected to the controller 110. The measurement unit 130 may measure the characteristics of the cartridge 1000 inserted into the diagnostic apparatus 100. [ The measuring unit 130 may measure the characteristics of at least a part of the area of the cartridge 1000. [ The measurement unit 130 may measure the optical characteristics of a part of the cartridge 1000.

The measurement unit 130 may measure the wavelength of light output from the cartridge 1000.

The measurement unit 130 may include a light emitting unit and a light receiving unit. When the measuring unit 130 includes the light emitting unit and the light receiving unit, the light emitting unit irradiates light to a part of the area of the cartridge 1000, and the light receiving unit measures light reflected from a part of the area of the cartridge 1000 can do. Alternatively, the light emitting unit may irradiate light to a part of the area of the cartridge 1000, and the light receiving unit may measure light transmitted through a part of the area of the cartridge 1000. The measurement unit 130 may measure the wavelength of the light reflected or transmitted from the cartridge 1000.

 The measurement unit 130 can measure a signal from a part of the cartridge 1000. The measurement unit 130 may measure a signal from a marker present in a partial area of the cartridge 1000. The measurement unit 130 may measure a wavelength from a marker present in a part of the cartridge 1000. The measurement unit 130 may measure the intensity of light from the markers present in a part of the cartridge 1000. The measurement unit 130 may measure the wavelength of light output by the marker located on the test line of the cartridge 1000. The measurement unit 130 may measure the intensity of light output by the marker located on the test line of the cartridge 1000.

The measurement unit 130 may measure signals output from different markers of the cartridge 1000. For example, the cartridge 1000 can measure light of a sandwich marker and a marker of a competitor that output different wavelengths.

The control unit 110 may measure the presence or absence of a specific component existing in the specimen using the signal measured by the measurement unit 130. [ The control unit 110 may analyze whether the specific antigen is present in the specimen injected into the cartridge 1000 based on the signal measured by the measuring unit 130. The control unit 110 may analyze the S1P concentration of the specimen based on the signal measured by the measuring unit 130. [ The control unit 110 may analyze the risk of osteoporotic fracture based on the signal measured by the measurement unit 130. The control unit 110 may provide the osteoporotic fracture risk according to the interval based on the signal measured by the measurement unit 130. [

3 is a view showing a cartridge according to the first embodiment.

Referring to FIG. 3, the cartridge 1000 according to the first embodiment may include a base 1001, a development pad 1010, and an absorption pad 1030. Or the cartridge 1000 includes a strip, which may include a base 1001, a deployment pad 1010, and an absorbent pad 1030.

The base 1001 may support the development pad 1010 and the absorption pad 1030. The base 1001 may have a higher hardness than the expansion pad 1010 and the absorption pad 1030.

The deployment pad 1010 may be located above the base 1001. Fluid may be introduced into the deployment pad 1010 and moved through the deployment pad 1010.

The development pad 1010 may be made of a material having hydrophilic properties. The deployment pad 1010 may be formed of a membrane. The deployment pad 1010 may include at least one of various synthetic polymers such as nitrocellulose, celluloses, cellulose acetate, polyethylene, and the like. Preferably, the deployment pad 1010 may be constructed of nitrocellulose.

The absorbent pad 1030 may be positioned on the base 1001. The absorbent pad 1030 may be positioned adjacent to the deployment pad 1010. The absorbent pad 1030 may contact the deployment pad 1010. The absorbent pad 1030 may be overlapped with the deployment pad 1010. At least a portion of the absorbent pad 1030 may cover the deployment pad 1010. In other words, at least a part of the area of the absorbent pad 1030 may be located at the top of the deployment pad 1010.

The absorbent pad 1030 can absorb the fluid. The absorption force of the absorption pad 1030 may be greater than the absorption force of the development pad 1010. The absorption pad 1030 may have higher hydrophilicity than the development pad 1010. The fluid may be introduced into the deployment pad 1010 and transferred to the absorption pad 1030. The fluid introduced into the development pad 1010 can be moved in the direction of the absorption pad 1030 by the absorption force of the absorption pad 1030. The absorbent pad 1030 can create a flow in the first direction of the fluid.

The absorbent pad 1030 may be composed of a membrane. The absorbent pad 1030 may include at least one of various synthetic polymers such as nitrocellulose, celluloses, cellulose acetate, polyethylene, and the like. Preferably, the absorbent pad 1010 may be constructed of celluloses.

The development pad 1010 may include a first region 1011, a second region 1013, and a third region 1015. The first region 1011 may be a region spaced apart from the absorption pad 1030 and the third region 1015 may be a region adjacent to the absorption pad 1030. The second region 1013 may be located between the first region 1011 and the third region 1015. The third region may contact the absorbent pad 1030.

Here, the first area 1011, the second area 1013, and the third area 1015 may be physically divided areas but may be virtually set areas. That is, the first region 1011, the second region 1013, and the third region 1015 may be formed integrally to configure the development pad 1010.

Alternatively, the first region 1011, the second region 1013, and the third region 1015 may have different characteristics. The first region 1011, the second region 1013, and the third region 1015 may be configured such that pads having different characteristics are connected to each other.

Although not shown, the first region 1011, the second region 1013, and the third region 1015 may have different pads connected to each other. In the case where the first region 1011, the second region 1013 and the third region 1015 are connected with different pads, a part of the first region 1011 is overlapped with the second region 1013 Can be located. At least a portion of the first region 1011 may cover the second region 1013. The second region 1013 may overlap the third region 1015. At least a portion of the second region 1013 may cover the third region 1015.

When the first region 1011, the second region 1013, and the third region 1015 have different pads connected to each other, the first region 1011 may be a sample pad into which a sample is introduced. Also, the second area 1013 may be a conjugation pad accommodated by a competitor. In this case, the sample pad and the conjugation pad may be made of a material different from the development pad. The sample pad and the conjugation pad may be made of glass fiber.

A test line 1040 may be located in the third region 1015. The test line 1040 may be formed in a direction perpendicular to the longitudinal direction of the development pad 1010. The test line 1040 may extend in a direction perpendicular to the moving direction of the fluid. When the fluid moves in the first direction, the test line 1040 may extend along a second direction perpendicular to the first direction.

The test line 1040 may include a plurality of antibodies 1041. The plurality of antibodies 1041 may be arranged along the test line 1040. The plurality of antibodies 1041 may be immobilized on the test line 1040. The test line 1040 may be a virtual line. The plurality of antibodies 1041 may be arranged along the second direction on the third region 1015 and the test lines may be configured by arranging the plurality of antibodies 1041. [

The plurality of antibodies 1041 may have corresponding characteristics. The plurality of antibodies 1041 may specifically bind to a specific substance. The plurality of antibodies 1041 can specifically bind to specific antigens.

The antibody 1041 may be an S1P antibody. The antibody 1041 can specifically bind to S1P.

A plurality of competitors 1050 may be introduced into the second region 1013. The plurality of competitors 1050 may be provided in a fixed form in the second region 1013. The plurality of competitors 1050 may be introduced from the outside into the second region 1013.

The competitor 1050 may include an antigen derivative 1051 and a marker 1053. The marker 1053 may be bound to the antigen derivative 1051.

The antigen derivative (1051) may be an S1P derivative. The antigen derivative 1051 may include a competitor antigen 1055 and a cross linker 1057. The competitor antigen (1055) can specifically bind to the antibody (1041). The cross linker 1057 can link the competitor antigen 1055 and the marker 1053.

The marker 1053 may include a fluorescent material. The markers 1053 may include gold, silver, europium, or quantum dot. The marker 1053 can output light having a specific wavelength. The marker 1053 can receive light and output light of a specific wavelength.

The specimen 1060 may be introduced into the first region 1011. The specimen 1060 may be introduced from the outside into the first region 1011. The specimen 1060 may be blood. The specimen 1060 may be the blood of the examinee. The specimen 1060 may include a fluid 1061 and a plurality of antigens 1063. The fluid 1061 may be moisture contained in the blood. The antigen 1063 may comprise S1P. The antigen 1063 can specifically bind to the antibody 1041.

The antigen 1063 and the competitor antigen 1055 may correspond to each other. The antigen 1063 and the competitor antigen 1055 may have a corresponding epitope. The antigen 1063 and the competitor antigen 1055 may have at least one antigenic determinant. Preferably, the antigen 1063 and the competitor antigen 1055 may have one antigenic determinant.

The antibody 1041 may bind to the antigen 1063 or the competitor antigen 1055. The antibody 1041 may bind to either the antigen 1063 or the competitor antigen 1055. The antibody 1041 may selectively bind to the antigen 1063 or the competitor antigen 1055.

The antibody 1041 may not bind to the other when bound to one of the antigen 1063 and the competitor antigen 1055. That is, when the antibody 1041 binds to the antigen 1063, the competitor antigen 1055 can not bind to the antibody 1041. In addition, when the antibody 1041 binds to the competitor antigen 1055, the antigen 1063 can not bind to the antibody 1041.

The antigen 1063 may have a smaller molecular weight than the competitor 1050. The size of the antigen 1063 may be smaller than the size of the competitor 1050. The mass of the antigen 1063 may be less than the mass of the competitor 1050. The competitor 1050 may have a molecular weight as high as that of the marker 1053 and the cross linker 1057 as compared to the antigen 1063 because the antigen 1063 and the competitor antigen 1055 correspond to each other. The competitor 1050 may have a mass that is as large as that of the marker 1053 and the cross linker 1057 as compared to the antigen 1063.

FIG. 4 is a view showing movement of a specimen and a competitor at a first time in the cartridge according to the first embodiment, FIG. 5 is a drawing showing movement of a specimen and a competitor at a second time in the cartridge according to the first embodiment; FIG. 6 is a view showing movement of a specimen and a competitor at the third time point in the cartridge according to the first embodiment, and FIG. 7 is a graph showing the movement of the specimen and the competitor at the fourth time point in the cartridge according to the first embodiment. Fig.

The cartridge 1000 according to the first embodiment may include a development pad 1010 and an absorption pad 1030. [ The cartridge 1000 is provided with the antibody 1040 fixed and the competitor 1050 introduced as shown in FIG. The competitor 1050 is introduced into the second region 1013 and the antibody 1040 is fixed in the third region 1015. [

The specimen 1060 may be introduced into the first region 1011. The specimen 1060 may include a fluid 1061 and a plurality of antigens 1063.

Referring to FIG. 4, the specimen 1060 introduced into the first region 1011 may move in a first direction. The specimen 1060 introduced into the first region 1011 can move toward the test line 1040.

The specimen 1060 includes a fluid 1061 and a plurality of antigens 1063 and the fluid 1061 may be absorbed and diffused into the deployment pad 1010. The diffusion of the fluid 1061 may be directional by the absorbent pad 1030. Since the absorption force of the absorption pad 1030 is higher than that of the development pad 1010, the fluid 1061 can move in the first direction by the absorption force of the absorption pad 1030.

The plurality of antigens 1063 can be moved in the first direction by the fluid 1061 without being absorbed by the deployment pad 1010. [ The plurality of antigens 1063 may move toward the test line 1040 by movement of the fluid 1061.

The fluid 1061 and the plurality of antigens 1063 may occupy an area on the deployment pad 1010 from a minimum deployment site to a maximum deployment site.

The minimum development point of the fluid 1061 may be defined as a point where the distance from the test line 1040 is the largest of the areas occupied by the fluid 1061 on the development pad 1010. The maximum development point of the fluid 1061 may be defined as a point where the distance from the test line 1040 to the area occupied by the fluid 1061 on the development pad 1010 is the smallest.

The minimum development point of the plurality of antigens 1063 may be defined as a point at which an antigen having the greatest distance from the test line 1040 among the plurality of antigens 1063 is located. The maximum development point of the plurality of antigens 1063 may be defined as a point at which an antigen having the smallest distance from the test line 1040 among the plurality of antigens 1063 is located.

The maximum developing point of the fluid 1061 at the first time point is shifted in the first direction from the maximum developing point of the fluid 1061 at the time when the specimen 1060 is introduced. That is, the distance between the maximum development point of the fluid 1061 at the first time point and the test line 1040 is determined by the maximum development point of the fluid 1061 at the time when the specimen 1060 is introduced, 1040).

The maximum development point of the plurality of antigens 1063 at the first time point is shifted in the first direction from the maximum development point of the plurality of antigens 1063 at the time point when the specimen 1060 is introduced. That is, the distance between the maximum development point of the plurality of antigens 1063 at the first time point and the test line 1040 is the maximum development point of the plurality of antigens 1063 at the time when the specimen 1060 is introduced Is shorter than the distance between the test lines (1040).

When the maximum development point of the fluid 1061 is compared with the maximum development point of the plurality of antigens 1063, the maximum development point of the fluid 1061 at the first point of time is the maximum development point of the plurality of antigens 1063 In the first direction. That is, the distance between the maximum development point of the fluid 1061 at the first time point and the test line 1040 is shorter than the distance between the maximum development point of the plurality of antigens 1063 and the test line 1040.

Since the plurality of antigens 1063 are moved in the first direction by the movement of the fluid 1061, the plurality of antigens 1063 can not be moved in the first direction more than the fluid 1061.

Referring to FIG. 5, the fluid 1061 moving in the first direction at a second time point after the first time passes through the first region 1011 and the second region 1013 and flows into the third region 1015 Can be moved.

The plurality of antigens 1063 can move in the first direction by the fluid 1061. The plurality of antigens 1063 can be moved toward the test line 1040 by the fluid 1061.

The fluid 1061 may pass through the second region 1013 and meet with the plurality of competitors 1050. The plurality of competitors 1050 fixed in the second region 1013 can be released by the fluid 1061. [ That is, the plurality of competitors 1050 fixed to the second region 1013 may be in a state movable with the fluid 1061. The plurality of competitors 1050 fixed in the second region 1013 can be activated and activated with the fluid 1061. [ All of the competitors 1050 fixed in the second area 1013 may be released or some of them may be released.

The plurality of competitors 1050 may be moved in the first direction by the fluid 1061. The plurality of competitors 1050 may move in the direction of the test line 1040 by movement of the fluid 1061.

The plurality of competitors 1050 can occupy an area on the development pad 1010 from a minimum development point to a maximum development point.

The minimum deployment point of the plurality of competitors 1050 may be defined as a point where the competitor having the greatest distance from the test line 1040 among the plurality of competitors 1050 is located. The maximum deployment point of the plurality of competitors 1050 may be defined as a point where the competitor having the smallest distance from the test line 1040 among the plurality of competitors 1050 is located.

The distance between the maximum development point of the fluid 1061 at the second time point and the test line 1040 is shorter than the distance between the maximum development point of the fluid 1061 at the first time point and the test line 1040 .

The distance between the maximum development point of the plurality of antigens 1063 at the second time point and the test line 1040 is longer than the distance between the maximum development point of the plurality of antigens 1063 at the first time point and the test line 1040 .

The maximum deployment points of the plurality of competitors 1050 at the second time point are shifted in the first direction from the maximum deployment points of the plurality of competitors 1050 at the first fixed time point of the plurality of competitors 1050 . That is, the distance between the maximum deployment point of the plurality of competitors 1050 at the second point of time and the test line 1040 is determined by the distance between the plurality of competitors 1050 at the first point in time when the plurality of competitors 1050 are fixed Is shorter than the distance between the maximum deployment point and the test line (1040).

The antigen 1063 may move at a first velocity in a first direction and the competitor 1050 may move at a second velocity in the first direction and the fluid 1061 may move at a third velocity in the first direction, You can move at speed.

The molecular weight of the molecule of the fluid 1061 is smaller than the molecular weight of the antigen 1063 and the competitor 1050. That is, the mass of the molecule of the fluid 1061 is smaller than the mass of the antigen 1063 and the competitor 1050. Thus, the third speed is faster than the first speed and the second speed.

The molecular weight of the antigen 1063 is smaller than the molecular weight of the competitor 1050. That is, the mass of the antigen 1063 is smaller than the mass of the competitor 1050. Thus, even though the antigen 1063 and the competitor 1050 are moved by the same fluid 1061, the first velocity is faster than the second velocity.

When the deviation of the speed is compared, the deviation between the first speed and the third speed may be larger than the deviation between the second speed and the third speed.

Since the speed of the antigen 1063 is faster than the speed of the competitor 1050, the maximum deployment point of the antigen 1063 and the maximum deployment point of the competitor 1050 after the competitor 1050 is unfixed, The distance between them increases. For example, the maximum deployment point of the antigen 1063 and the maximum deployment point of the competitor 1050 are different by a first distance at a particular point in time after the competitor 1050 is unfixed, The first distance is smaller than the second distance if the maximum deployment point of the antigen 1063 and the maximum deployment point of the competitor 1050 differ by a second distance. The point of time after the specific point of time and the point of time after the point of time may be arbitrarily selected from the time when the competitor 1050 is released to the point of time before the maximum development point of the plurality of antigens 1063 reaches the test line 1040 .

Referring to FIG. 6, a portion of the fluid 1061 moving in the first direction from the third point of time after the second point of time may reach the absorption pad 1030. A portion of the fluid 1061 may be absorbed by the absorbent pad 1030. At the third time point, the maximum development point of the fluid 1061 can reach the absorption pad 1030.

The plurality of antigens 1063 may reach the test line 1040 by movement of the fluid 1061.

As the plurality of antigens 1063 reach the test line 1040, at least any one of the plurality of antigens 1063 may be bound to the antibody 1041 fixed to the development pad 1010. The antigen 1063 combined with the antibody 1041 stops moving and can be fixed in position with the antibody 1041 on the test line 1040.

The plurality of antibodies 1041 may bind to the antigen 1040 in proportion to the number of the antigens 1040. The plurality of antibodies 1041 may bind to the antigen 1040 in proportion to the concentration of the antigen 1040. As the number of antigens 1040 in the specimen 1030 increases, the number of antibodies 1041 binding to the antigen 1040 may increase. As the concentration of the antigen 1040 in the specimen 1030 is higher, the antibody 1041 binding to the antigen 1040 may be increased.

In contrast, as the number of the antigens 1040 in the specimen 1030 is smaller, unbound antibodies that can not bind to the antigen 1040 can be increased. As the concentration of the antigen 1040 in the specimen 1030 is lower, unbound antibody that can not bind to the antigen 1040 may increase.

The plurality of competitors 1050 may move in the first direction in accordance with the movement of the fluid 1061. The plurality of competitors 1050 move toward the test line 1040 but have not reached the test line 1040.

Since the plurality of antigens 1063 are fixed on the test line 1040, the distance between the plurality of antigens 1063 and the competitor 1050 is gradually reduced.

The speed of the plurality of antigens 1063 is faster than the speed of the plurality of competitors 1050 so that any one of the antigens 1063 reaches the test line 1040 before reaching the test line 1040 The competitor 1050 does not exist.

Since the plurality of competitors 1050 are released by the fluid 1061, the plurality of competitors may move in a first direction after a predetermined time has elapsed after the fluid 1061 and the plurality of competitors 1050 have met, Lt; / RTI > Therefore, there is no competitor 1050 reaching the test line 1040 before any of the plurality of antigens 1063 reaches the test line 1040.

Referring to FIG. 7, at a fourth time point after the third time point, the fluid 1061 may further move in the first direction. The absorption pad 1030 can absorb more fluid 1061 than the third time point.

The plurality of competitors 1040 may reach the test line 1040 by movement of the fluid 1061. Some of the plurality of competitors 1040 may bind unbound antibodies that are not associated with the antigen 1063. A competitor of the plurality of competitors 1040 that is not associated with the unbound antibody can reach the absorbent pad 1030 by the fluid 1061.

A competitor of the plurality of competitors 1040 coupled with the unbound antibody may be fixed in the test line 1040. As the plurality of competitors 1040 are fixed in the test line 1040, the markers 1053 included in the competitor 1040 can also be fixed in position.

 The plurality of competitors 1050 may combine with the antibody 1041 in inverse proportion to the number of the antigens 1040. As the number of antigens 1040 in the specimen 1030 increases, the number of competitors 1050 that bind to the antibody 1041 may be reduced. The higher the concentration of the antigen 1040 in the specimen 1030, the fewer the competitor 1050 that binds to the antibody 1041. If the concentration of the antigen 1040 in the sample 1030 is sufficiently high so that all of the antibodies 1041 immobilized on the test line 1040 bind to the antigen 1040 and no unbound antibody is present, There is no competitor 1050 associated with each of the competitors 1010 and 1041 and all of the competitors 1050 can reach the absorbing pad 1030. [

In contrast, as the number of antigens 1040 in the specimen 1030 is smaller, the number of competitors 1050 binding to the antibody 1041 may increase. As the concentration of the antigen 1040 in the specimen 1030 is lower, the number of competitors 1050 binding to the antibody 1041 may increase. All of the antibodies 1041 fixed to the test line 1040 may be coupled to the competitor 1050 when the concentration of the antibody 1041 in the specimen 1030 is extremely low.

The number of competitors 1050 should be such that an amount of the competitor 1050 can be combined with all of the antibodies 1041 fixed to the test line 1040. [ That is, in the second region 1013, a number of competitors 1050 corresponding to the antibody 1041 fixed to the test line 1040 may be introduced. Or the number of competitors 1050 introduced into the second region 1013 may be equal to or greater than the number of antibodies 1041 fixed to the test line 1040.

The diagnostic range of the specimen 1030 can be widened by setting the number of competitors 1050 introduced to be larger than the number of antibodies 1041 fixed to the test line 1040. That is, by increasing the upper limit of the number of competitors 1040 coupled to the antibody 1041, the diagnostic accuracy of the diagnostic device 100 can be increased.

The diagnostic apparatus 100 may calculate the concentration of the antigen 1040 contained in the specimen 1030 based on the number of competitors 1050 whose positions are fixed in the test line 1040. [ The diagnostic apparatus 100 measures the concentration of the antigen 1040 included in the specimen 1030 by measuring the signal of the competitor 1050 whose position is fixed to the test line 1040 by the measuring unit 130 Can be calculated.

The measuring unit 130 may measure the wavelength from the marker 1053 of the competitor 1050 whose position is fixed on the test line 1040. The measurement unit 130 may measure the intensity of light from the marker 1053 of the test line 1040. The measurement unit 130 may measure the intensity of light of a specific wavelength output from the marker 1053 of the test line 1040.

The intensity of light output from the marker 1053 changes according to the number of competitors 1050 fixed in the test line 1040 and the diagnostic instrument 100 measures the intensity of the light The concentration of the antigen 1040 contained in the sample 1030 can be calculated. Alternatively, the intensity of light of a specific wavelength outputted from the marker 1053 is changed in accordance with the number of competitors 1050 whose positions are fixed in the test line 1040, The concentration of the antigen 1040 contained in the specimen 1030 can be calculated by measuring the intensity of light. Alternatively, the wavelength of the light output from the marker 1053 is changed in accordance with the number of competitors 1050 fixed in the test line 1040, and the diagnostic device 100 measures the wavelength of the light The concentration of the antigen 1040 contained in the specimen 1030 can be calculated.

If the competitor 1050 comprises an S1P derivative and the antibody 1041 is an antibody that specifically binds to S1P, the diagnostic device 100 may detect a sample 1060 through a signal from the test line 1040, Can be calculated. In this case, the diagnosis apparatus 100 can analyze the risk of osteoporotic fracture through the S1P concentration in the calculated sample 1060.

In the case of the first embodiment, it is possible to set the competitor 1050 to reach the test line 1040 after at least one antigen 1063 reaches the test line 1040 in the cartridge 1000, There is an effect that can be improved. For example, if the competitor 1050 first reaches the test line 1040 and binds with the immobilized antibody 1041 before the antigen 1063 reaches the test line 1040, The number of competitors 1050 to be bound to the antibody 1041 can be determined regardless of the concentration of the antigen 1063, and the measurement accuracy can be lowered. Extremely, when the antigen 1063 reaches the test line 1040 after all of the competitor 1050 has reached the test line 1040, all the antibodies immobilized on the test line 1040 will be detected by the competitor 1050), and the diagnostic apparatus 100 can obtain the same result regardless of the concentration of the antigen of the specimen 1060. It is therefore possible to set the competitor 1050 to reach the test line 1040 after at least one antigen 1063 in the cartridge 1000 reaches the test line 1040, have.

8 is a view showing a cartridge according to the second embodiment.

The cartridge according to the second embodiment is different from the competitor in the first embodiment, and the remaining configuration is the same. Therefore, in describing the second embodiment, the same reference numerals are assigned to the same components as those of the first embodiment, and a detailed description thereof is omitted.

Referring to FIG. 8, the cartridge 1000 according to the second embodiment may include a base 1001, a development pad 1010, and an absorption pad 1030.

The development pad 1010 may include a first region 1011, a second region 1013, and a third region 1015.

The specimen 1060 may be introduced into the first region 1011. The specimen 1060 may include a fluid 1061 and an antigen 1063.

A test line 1040 may be located in the third region 1015. The test line 1040 may include a plurality of antibodies 1041.

A plurality of competitors 1050 may be introduced into the second region 1013. The competitor 1050 may include an antigen derivative 1051, a marker 1053, and a protein 1059. The marker 1053 may be bound to the antigen derivative 1051 through the protein 1059. The protein (1059) may bind to the marker (1053) and the antigen derivative (1051).

The antigen derivative (1051) may be an S1P derivative. The antigen derivative 1051 may include a competitor antigen 1055 and a cross linker 1057. The cross linker 1057 can link the scavenger competitor antigen 1055 and the protein 1059.

The antigen derivative 1051 is bound to the marker 1053 through the protein 1059 so that the competitor 1050 can be manufactured through the binding of the marker 1053. [ That is, binding of the marker 1053 to the protein 1059 having a relatively large number of exposed functional groups can increase the binding probability of the marker 1053, thereby increasing the synthesis efficiency of the competitor 1050.

Also, by using the competitor 1050 including the protein 1059, the diagnostic accuracy is improved compared with the first embodiment.

Since the competitor 1050 includes a protein, the molecular weight of the competitor 1050 is larger than that of the competitor of the first embodiment. Further, the time for releasing the fixing by the fluid 1061 can be increased. Thereby, the effect that the deviation of the time for the antigen 1063 of the specimen 1060 to reach the test line 1040 and the time for the competitor 1050 to reach the test line 1040 becomes larger, have. That is, the competitor 1050 reaches the test line 1040 after the antigen 1063 of the specimen 1060 sufficiently bonds with the antibody 1041 of the test line 1040, The diagnostic accuracy can be improved by reducing the probability that the antigen 1063 can bind to the antibody 1041 before binding to the antibody 1041. [

9 is a view showing a cartridge according to the third embodiment.

The cartridge according to the third embodiment is the same as the first embodiment except that the competitor is provided through the competitor container as compared with the first embodiment. Therefore, in describing the third embodiment, the same reference numerals are assigned to the components common to those of the first embodiment, and a detailed description thereof is omitted.

9, the cartridge 1000 according to the third embodiment may include a base 1001, a development pad 1010, an absorbent pad 1030, and a competitor container 1058. [

The expansion pad 1010 may include a first region 1011, a second region 1012, and a third region 1015. The first region 1011 may be a region spaced apart from the absorption pad 1030 and the third region 1015 may be a region adjacent to the absorption pad 1030. The first region 1011 and the third region 1015 may be located in adjacent regions. The first region 1011 and the third region 1015 may be in contact with each other. The first region 1011 and the third region 1015 may be arranged along a first direction.

The specimen 1060 may be introduced into the first region 1011. The specimen 1060 may include a fluid 1061 and a plurality of antigens 1063.

A test line 1040 may be located in the third region 1015. The test line 1040 may include a plurality of antibodies 1041.

The second region 1012 may be a side surface of the development pad 1010. The second region 1012 may be a side surface of the development pad 1010 in a second direction perpendicular to the first direction. The second region 1012 may be a side surface of the third region 1015. The second region 1012 may be the side of the third region 1015 in the second direction.

The second region 1012 may be a part of the side surface of the third region 1015. The second region 1012 may be a side surface of a portion of the third region 1015 where the test line 1040 is located.

The competitor container 1058 may be located in an area adjacent to the second area 1012. A plurality of competitors 1050 may be accommodated in the competitor container 1058.

The competitor vessel 1058 may be formed, for example, in a piston shape. Inside the competing container 1058, a protective coating may be formed to prevent the plurality of competitors 1050 from adhering to the interior of the competitor container 1058. The protective coating may be composed of a hydrophilic material.

The competitor container 1058 may introduce the plurality of competitors 1050 into the second region 1012. The plurality of competitors 1050 may be introduced through the second region 1012. [ The competitor container 1058 may communicate a plurality of competitors 1050 to the third region 1015 through the second region 1012. [

The competitor container 1058 may provide the plurality of competitors 1050 to the second region 1012 by operating in a state of accommodating the plurality of competitors 1050. [ The competitor container 1058 may provide the plurality of competitors 1050 to the second region 1012 by a mechanical configuration within the cartridge 1000. The competitor container 1058 may provide the plurality of competitors 1050 to the second area 1012 under the control of the diagnostic device 100. [ The competitor container 1058 may provide the plurality of competitors 1050 to the second region 1012 under the control of the control unit 110 of the diagnostic apparatus 100. [ The competitor container 1058 may provide the plurality of competitors 1050 to the second area 1012 by a mechanical configuration within the diagnostic device 100. [

In the operation of the cartridge 1000 according to the third embodiment, first, the specimen 1060 is introduced onto the first region 1011. The fluid 1061 contained in the specimen 1060 moves in the first direction due to the absorption force of the absorption pad 1030. The plurality of antigens 1063 are moved in the first direction by the movement of the fluid 1061. The plurality of antigens 1063 may be moved in the first direction and moved to the test line 1040 of the third region 1015. The plurality of antigens 1063 is coupled with the antibody 1041 immobilized on the test line 1040 and the antigen 1063 binds with the antibody 1041.

The competitor container 1058 may be configured such that after one of the plurality of antigens 1063 reaches the test line 1040, the plurality of competitors 1050 are connected to the third region 1012 through the second region 1012, Area 1015, as shown in FIG. The competitor container 1058 is configured to allow the plurality of contenders 1050 to communicate with the third region 1015 through the second region 1012 after all of the plurality of antigens 1063 reach the test line 1040. [ As shown in FIG.

The competitor container 1058 may be configured to allow the plurality of competitors 1050 to communicate with the third region 1012 through the second region 1012 when the maximum deployment point of the plurality of antigens 1063 reaches at least the test line 1040. [ (1015). The competitor container 1058 may be configured to communicate the plurality of competitors 1050 to the third region 1012 via the second region 1012 when the minimum deployment point of the plurality of antigens 1063 reaches the test line 1040. [ 1015).

The control unit 110 of the diagnostic apparatus 100 may control the operation of the competitor container 1058 after a predetermined time elapses after the specimen 1060 is injected into the cartridge 1000, Lt; / RTI >

Alternatively, the diagnostic apparatus 100 may measure the presence of any one of the plurality of antigens 1063 on the test line 1040, and then operate the competitor container 1058. In this case, the controller 110 of the diagnostic apparatus 100 may measure the signal from the test line 1040 through the measurement unit 130 to operate the competitor vessel 1058.

The control unit 110 of the diagnostic apparatus 100 may operate the competitor container 1058 when the signal change of the test line 1040 is measured through the measurement unit 130. [ The control unit 110 of the diagnostic device 100 may operate the competitor container 1058 when the signal change of the test line 1040 measured through the measurement unit 130 is within a predetermined range. The diagnostic accuracy of the diagnostic device 100 may be improved by operating the competitor container 1058 after measuring whether the antigen of one of the plurality of antigens 1063 has arrived on the test line 1040 have.

The cartridge according to the second embodiment can provide the plurality of competitors 1050 in a region adjacent to the test line 1040 through a separate riveting vessel 1058 as compared to the cartridge according to the first embodiment, It is possible to prevent a plurality of competitors 1050 from being lost on the pad 1010. It is also possible to precisely control the time point of presentation of the competitor 1050 and prevent the competitor 1050 from combining with the antibody 1043 prior to the antigen 1063, It is effective.

10 is a view showing a cartridge according to the fourth embodiment.

The cartridge according to the fourth embodiment is the same as the first embodiment except that the development speed of the area corresponding to the test line is made slower than that of the other development pads. Therefore, in describing the fourth embodiment, the same reference numerals are assigned to the components common to those of the first embodiment, and a detailed description thereof will be omitted.

10, the cartridge 1000 according to the fourth embodiment may include a base 1001, a development pad 1010, an absorbent pad 1030, and a competitor container 1058. [

The development pad 1010 may include a first region 1011, a second region 1013, a third region 1015, and a fourth region 1017.

The first region 1011 to the third region 1015 may be sequentially arranged along the first direction. The first region 1011 may be a region spaced apart from the absorption pad 1030 and the third region 1015 may be a region adjacent to the absorption pad 1030. The second region 1013 may be located between the first region 1011 and the third region 1015.

The fourth region 1017 may be located within the third region 1015. The fourth region 1017 may extend in the second direction. The distance between the fourth region 1017 and the absorption pad 1030 may be shorter than the distance between the fourth region 1017 and the boundary between the second region 1013 and the third region 1015.

The fourth region 1017 may be formed of the same material as the third region 1015 and the fourth region 1017 may be formed of a different material from the third region 1015. The fourth region 1017 may have characteristics different from those of the third region 1015. The fourth region 1017 may provide a slower development rate than the third region 1015. [ The fourth region 1017 may have a lower absorption rate than the third region 1015. The fourth region 1017 may have a lower hydrophilicity than the third region 1015.

A test line 1040 may be located on the fourth region 1017. The test line 1040 may include a plurality of antibodies 1041. The plurality of antibodies 1041 may be located on the fourth region 1017.

In the operation of the cartridge 1000 according to the fourth embodiment, first, the specimen 1060 is introduced onto the first region 1011. The fluid 1061 contained in the specimen 1060 moves in the first direction due to the absorption force of the absorption pad 1030. The plurality of antigens 1063 are moved in the first direction by the movement of the fluid 1061. The plurality of antigens 1063 are moved in the first direction and are introduced into the fourth region 1017 through the second region 1013 and the third region 1015.

The fluid 1061 may move at a slower rate than the third region 1015 in the fourth region 1017. [ The fluid 1061 moves at a relatively high speed when passing through the third region 1015 adjacent to the second region 1013 and when passing through the fourth region 1017, And moves at a comparatively high speed when passing through the fourth region 1017 and the third region 1015 adjacent to the absorption pad 1030. [

Since the plurality of antigens 1063 are moved by the movement of the fluid 1061, the plurality of antigens 1063 can be moved at a speed corresponding to the velocity of the fluid 1061. That is, the speed at which the plurality of antigens 1063 move on the fourth region 1017 may be slower than the speed at which the plurality of antigens 1063 move on the third region 1015.

The plurality of antigens 1063 move at a comparatively slow rate on the test line 1040 to increase the probability that the antigen 1063 binds to the antibody 1041. That is, the probability of being absorbed into the absorption pad 1030 without binding to the unbound antibody in the antigen 1063 passing through the test line 1040 can be reduced. The diagnostic accuracy of the diagnostic device 100 can be improved by increasing the probability of binding between the plurality of antigens 1063 and the antibody 1041. [

The plurality of competitors 1050 are also moved in the first direction by movement of the fluid 1061. The plurality of competitors 1050 may move in the first direction and move to the test line 1040 of the fourth region 1015. [ Since the plurality of competitors 1050 are also moved by the movement of the fluid 1061, the plurality of competitors 1050 can be moved at a speed corresponding to the speed of the fluid 1061. That is, the speed at which the plurality of competitors 1050 move on the fourth region 1017 may be slower than the speed that moves the third region 1015.

The plurality of competitors 1050 may also move at a relatively slow rate on the test line 1040 to increase the probability that the competitor 1050 will combine with the antibody 1041. That is, the probability of being absorbed into the absorption pad 1030 without being bound to the unbound antibody in the competitor 1050 passing through the test line 1040 can be reduced. The diagnostic accuracy of the diagnostic device 100 can be improved by raising the probability of binding of the plurality of competitors 1050 and the antibody 1041.

FIG. 11 is a view showing a cartridge according to a fifth embodiment, and FIG. 12 is a view showing a state in which the reaction of the cartridge according to the fifth embodiment is completed.

The cartridge according to the fifth embodiment is a cartridge capable of measuring multi-targets. The cartridge according to the fifth embodiment differs from the first embodiment in that the antibody, the competitor, etc., which are introduced to measure the multi-target, and the remaining configuration are the same. Therefore, in describing the fifth embodiment, the same reference numerals are assigned to the components common to those of the first embodiment, and a detailed description thereof will be omitted.

Referring to FIG. 11, the cartridge 1000 according to the fifth embodiment may include a first area 1011, a second area 1013, and a third area 1015. The first region 1011, the second region 1013, and the third region 1015 may be arranged along the first direction. The first region 1011 may be a region spaced apart from the absorption pad 1030 and the third region 1015 may be a region adjacent to the absorption pad 1030. The second region 1013 may be located between the first region 1011 and the third region 1015.

The first test line 1040 and the second test line 1070 may be disposed in the third region 1015. [ The first test line 1040 and the second test line 1070 may extend along the second direction. The first test line 1040 and the second test line 1070 may be parallel to each other. The first test line 1040 and the second test line 1070 may be spaced apart from each other. The first test line 1040 may be located in an area adjacent to the absorption pad 1030 and the second test line 1070 may be located in an area adjacent to the second area 1013 .

The first test line 1040 may include a plurality of first antibodies 1041. The second test line 1040 may include a plurality of second antibodies 1071. The first antibody 1041 and the second antibody 1071 can specifically bind to different antigens. The antigen that binds to the first antibody 1041 is not bound to the second antibody 1071 and the antigen that binds to the second antibody 1071 may not bind to the first antibody 1041.

The first antibody 1041 may be an antibody used in a competitive immunological reaction. The second antibody 1071 may be an antibody used in a sandwich immunoassay.

In the second region 1013, a plurality of competitors 1050 and a plurality of sandwiching conductors 1080 may be introduced.

The plurality of competitors 1050 may include an antigen derivative 1051 and a marker 1053. The antigen derivative (1051) may include the competitor antigen (1055) and the cross linker (1057).

The sandwich derivative 1080 may include a label antibody 1081 and a sandwich marker 1083. The label antibody 1081 may be combined with the sandwich marker 1083. [ The label antibody 1081 can specifically bind to the same substance as the second antibody 1071. The label antibody 1081 may be bound to the same antigen as the second antibody 1071.

The sandwich marker 1081 may be formed of a fluorescent material. The sandwich marker 1081 may be formed of a material different from the markers 1053 of the competitor 1050. The sandwich marker 1081 may output light having a wavelength different from that of the marker 1053 of the competitor 1050. The sandwich marker 1081 and the markers 1053 of the competitor 1050 can output wavelengths in other regions to such an extent that measurement is possible.

Alternatively, the sandwich marker 1081 and the marker 1053 may be composed of the same material. The sandwich marker 1081 may output light having the same wavelength as that of the marker 1053.

The specimen 1060 may be introduced into the first region 1011. The specimen 1060 may include a fluid 1061, a first antigen 1065, and a second antigen 1067. The first antigen 1065 and the second antigen 1067 may be different materials. The first antigen 1065 and the second antigen 1067 can specifically bind to different antibodies.

For example, the first antigen 1065 can specifically bind to the first antibody 1041, and the second antigen 1067 can bind specifically to the second antibody 1071 and the label antibody 1081, ≪ / RTI >

When the first antigen 1065 binds to the first antibody 1041, the first antigen 1065 does not bind to the second antibody 1071 and the labeled antibody 1081. [ Further, when the second antigen 1067 binds with the second antibody 1071 and the label antibody 1081, it does not bind to the first antibody 1041.

The first antigen 1065 may be a substance having a relatively small molecular weight as compared to the second antigen 1067. The first antigen 1065 may have one antigenic determinant and the second antigen 1067 may have at least two antigenic determinants.

In the operation of the cartridge 1000 according to the fifth embodiment, the specimen 1060 may be introduced into the first region 1011 as shown in FIG.

The fluid 1061 may move in the first direction. The first antigen 1065 and the second antigen 1067 may also be moved in the first direction by movement of the fluid 1061. By movement of the fluid 1061, the competitor 1050 and the sandwich derivative 1080 can also be moved in the first direction.

The first antigen 1065 may arrive at the first test line 1040 before the competitor 1050. Wherein the first antigen 1065 is associated with the first antibody 1041 and the plurality of competitors 1050 is in the first test 1045 after the first antigen 1065 is associated with the first antibody 1041. [ Line 1040. < / RTI > An unbound antibody that is not associated with the first antigen 1065 may be combined with the plurality of competitors 1050. The competitor 1050 that can not bind to the first antibody 1041 can reach the absorbent pad 1030.

The second antigen 1067 may move to the second test line 1070. The second antigen 1067 may be coupled to the sandwich conductor 1080 in the course of moving to the second test line 1070. Alternatively, the second antigen 1067 may be coupled to the sandwich conductor 1080 after being moved to the second test line 1070. Alternatively, a part of the second antigen 1067 may be combined with the sandwich derivative 1080 in the course of moving to the second test line 1070, and the remaining part of the second antigen 1067 may be combined with the 2 test line 1070 before being coupled to the sandwich conductor 1080.

The process of coupling the second antigen 1067 with the sandwich derivative 1080 in the process of moving to the second test line 1070 is performed by the fluid 1061, The second antigen 1067 is coupled with the sandwich derivative 1080 that is released by the fluid 1061 and the second antigen 1067 is coupled with the sandwich derivative 1080, May be moved to the test line 1070 and combined with the second antibody 1071.

The process of combining the second antigen 1067 with the sandwich derivative 1080 after the second antigen 1067 is moved to the second test line 1070 may be performed by the fluid 1061, The second antigen 1067, which has moved to the test line 1070, may be combined with the second antibody 1071. At the same time, the sandwich derivative 1080, which is released by the fluid 1061, moves in the first direction, and after the second antigen 1067 is combined with the second antibody 1071, The test line 1070 is reached. The sandwich derivative 1080 may be combined with the second antigen 1067, which is fixed on the second test line 1070.

When the movement and reaction of the first antigen 1065, the second antigen 1067, the competitor 1050, and the sandwich derivative 1080 by the fluid 1061 are completed, the state shown in FIG. 12 is obtained.

The first antigen 1065 or the competitor 1050 may be combined on the first antibody 1041 fixed to the first test line 1040.

A second antigen 1067 may be coupled to the second antibody 1071 fixed to the second test line 1070 and a sandwich derivative 1080 may be coupled to the second antigen 1067.

The diagnostic apparatus 100 may detect the presence or absence of different targets and the concentrations of different targets by measuring signals of the third region 1015. The diagnostic apparatus 100 measures a signal of the third region 1015 and determines whether or not the first antigen 1065 included in the specimen 1060 is present, the concentration of the first antigen 1065, 1067) and the concentration of the second antigen 1067 can be measured.

The diagnostic apparatus 100 may measure the presence or absence and presence or absence of the first antigen 1065 and the second antigen 1067 through the wavelength of light output from the third region 1015. The diagnostic apparatus 100 simultaneously measures the signals of the first test line 1040 and the second test line 1070 to calculate intensity of light for each wavelength and outputs the intensity of the light to the first antigen 1065 and the second antigen 1067 ) And the respective concentrations can be measured. The diagnostic device 100 outputs signals of the first test line 1040 and the second test line 1070 at the same time so that the diagnostic device 100 outputs the signals of the first test line 1040 and the second test line 1070 at the same time The presence and the respective concentrations of the first antigen 1065 and the second antigen 1067 can be measured.

The diagnostic apparatus 100 measures signals of the first test line 1040 and the second test line 1070 to determine whether the first antigen 1065 and the second antigen 1067 are present, The concentration can be measured. In this case, even if the marker 1040 and the sandwich marker 1083 output light having the same wavelength, the diagnostic apparatus 1065 determines whether or not the first antigen 1065 and the second antigen 1067 are present, The concentration can be measured. That is, the diagnostic apparatus 100 measures the light of the first test line 1040 and measures the light of the second test line 1070, It is possible to measure the presence or absence and presence of each concentration of the sample 1067.

In the fifth embodiment, the existence and concentration of different antigens can be measured using one development pad, and the detection efficiency is improved. In addition, there is an effect that diagnosis of a plurality of diseases can be performed using one cartridge.

When the first antibody 1041 is an S1P antibody, the second antibody 1071 may be composed of an antibody capable of detecting a bone marker to simultaneously measure not only the S1P concentration but also the bone marker concentration to determine the risk of osteoporotic fracture There is an effect that can be accurately measured.

FIG. 13 is a view showing a cartridge according to the sixth embodiment, and FIG. 14 is a view showing a state in which the reaction of the cartridge according to the sixth embodiment is completed.

The cartridge according to the sixth embodiment is a cartridge capable of measuring multi-targets. The cartridge according to the sixth embodiment differs from the cartridge according to the fifth embodiment in the cartridge structure for measuring the multi-target, and the remaining configuration is the same. Therefore, the same reference numerals are assigned to the same components as those of the sixth embodiment, and a detailed description thereof will be omitted.

Referring to FIG. 13, the cartridge 1000 according to the sixth embodiment may include a first area 1011, a second area 1013, and a third area 1015. The first region 1011, the second region 1013, and the third region 1015 may be arranged along the first direction. The first region 1011 may be a region spaced apart from the absorption pad 1030 and the third region 1015 may be a region adjacent to the absorption pad 1030. The second region 1013 may be located between the first region 1011 and the third region 1015.

The second area 1013 and the third area 1015 may include a first partition area 1091 and a second partition area 1093. A boundary film 1090 may be formed on the boundary between the first and second divided regions 1091 and 1093. The boundary film 1090 may extend along the first direction, and the first and second divided regions 1091 and 1093 may extend along the first direction.

The boundary film 1090 may be a film that prevents the material of the first partition 1091 and the material of the second partition 1093 from moving relative to each other. The boundary film 1090 can prevent the material in the first region 1091 of the second region 1013 and the third region 1015 from moving to the second region 1093, It is possible to prevent the material in the second division area 1093 from moving to the first division area 1091. [ The boundary film 1090 can prevent the first antigen 1065, the second antigen 1067 and the sandwich derivative 1080 from moving from the first segment 1091 to the second segment 1093 , The boundary film 1090 can prevent the first antigen 1065, the second antigen 1067 and the competitor 1050 from moving from the second segment 1093 to the first segment 1091 have. The boundary film 1090 may prevent movement of the fluid 1060 and the fluid 1060 may move below the boundary film 1090.

The boundary film 1090 may be provided on the top surface of the development pad 1010. Or the boundary film 1090 may be provided in such a manner that the boundary film 1090 is fitted in the groove formed in the development pad 1010 with a thickness corresponding to the development pad 1010.

In the third region 1015, a first test line 1040 and a second test line 1070 may be formed. The first test line 1040 may be formed in the first divided region 1091 of the third region 1015 and the second test line 1090 may be formed in the second divided region 1093 .

The first test line 1040 may be constituted by a first antibody 1041 and the second test line 1070 may be constituted by the second antibody 1071.

In the second region 1013, a plurality of competitors 1050 and a plurality of sandwiching conductors 1080 may be introduced.

The plurality of competitors 1050 may include an antigen derivative 1051 and a marker 1053. The antigen derivative (1051) may include the competitor antigen (1055) and the cross linker (1057).

The sandwich derivative 1080 may include a label antibody 1081 and a sandwich marker 1083.

The specimen 1060 may be introduced into the first region 1011. The specimen 1060 may include a fluid 1061, a first antigen 1065, and a second antigen 1067. The first antigen 1065 and the second antigen 1067 may be different materials. The first antigen 1065 and the second antigen 1067 can specifically bind to different antibodies.

Referring to the operation of the cartridge 1000 according to the sixth embodiment, the specimen 1060 may be introduced into the first region 1011 as shown in FIG.

The fluid 1061 may move in a first direction. The fluid 1061 can be uniformly moved over the entire region of the second region 1013 and the third region 1015. [ When the fluid 1061 does not pass through the boundary film 1090, the fluid 1061 introduced into the first region 1011 is uniformly distributed in the first and second divided regions 1091 and 1093, And move in the first direction.

By the movement of the fluid 1061, the first antigen 1065 and the second antigen 1067 can also be moved in the first direction. The first antigen 1065 and the second antigen 1067 are randomly provided on the first region 1011 so that the first antigen 1065 is divided into the first region 1091 and the second region 1061 1093 and is introduced into the second region 1013 and the second antigen 1067 is uniformly distributed in the first region 1091 and the second region 1093 and is introduced into the second region 1013 Can be introduced.

A plurality of competitors 1050 introduced into the first divisional region 1091 of the second region 1013 by the movement of the fluid 1061 can be moved in the first direction within the first divisional region 1091 have. The plurality of sandwiching conductors 1080 introduced into the second division region 1093 of the second region 1013 by the movement of the fluid 1061 are arranged in the second division region 1093 in the first direction Lt; / RTI >

The first antigen 1065 may reach the first test line 1040 existing in the first segment 1091 before the competitor 1050. [ Wherein the first antigen 1065 is associated with the first antibody 1041 and the plurality of competitors 1050 is in the first test 1045 after the first antigen 1065 is associated with the first antibody 1041. [ Line 1040. < / RTI > An unbound antibody that is not associated with the first antigen 1065 may be combined with the plurality of competitors 1050. The competitor 1050 that can not bind to the first antibody 1041 can reach the absorbent pad 1030.

The second antigen 1067 may move to the second test line 1070 located in the second segment 1093. [ The second antigen 1067 may be coupled to the sandwich conductor 1080 in the course of moving to the second test line 1070. Alternatively, the second antigen 1067 may be coupled to the sandwich conductor 1080 after being moved to the second test line 1070. Alternatively, a part of the second antigen 1067 may be combined with the sandwich derivative 1080 in the course of moving to the second test line 1070, and the remaining part of the second antigen 1067 may be combined with the 2 test line 1070 before being coupled to the sandwich conductor 1080.

When the movement and reaction of the first antigen 1065, the second antigen 1067, the competitor 1050, and the sandwich derivative 1080 by the fluid 1061 are completed, the state shown in FIG. 14 is obtained.

The first antigen 1065 or the competitor 1050 may be combined on the first antibody 1041 fixed to the first test line 1040.

A second antigen 1067 may be coupled to the second antibody 1071 fixed to the second test line 1070 and a sandwich derivative 1080 may be coupled to the second antigen 1067.

The diagnostic apparatus 100 may detect the presence or absence of different targets and the concentrations of different targets by measuring signals of the third region 1015. The diagnostic apparatus 100 measures a signal of the third region 1015 and determines whether or not the first antigen 1065 included in the specimen 1060 is present, the concentration of the first antigen 1065, 1067) and the concentration of the second antigen 1067 can be measured.

The diagnostic apparatus 100 measures signals of the first test line 1040 and the second test line 1070 to determine whether the first antigen 1065 and the second antigen 1067 are present, The concentration can be measured. In this case, even if the marker 1040 and the sandwich marker 1083 output light having the same wavelength, the diagnostic apparatus 1065 determines whether or not the first antigen 1065 and the second antigen 1067 are present, The concentration can be measured. The diagnostic apparatus 100 may measure the presence or concentration of the first antigen 1065 by measuring a signal of the first divided region 1091. [ The diagnostic apparatus 100 can measure the presence and concentration of the second antigen 1067 by measuring a signal of the second division area 1093. [

Compared with the fifth embodiment, the sixth embodiment can reduce the errors that may be caused by non-specific binding by measuring the presence or absence of different antigens by separating the pads during the developing process. Therefore, it is possible to more accurately diagnose a plurality of diseases using one cartridge.

FIG. 15 is a view showing a cartridge according to a seventh embodiment, and FIG. 16 is a view showing a state in which the reaction of the cartridge according to the seventh embodiment is completed.

The cartridge according to the seventh embodiment is the same as the first embodiment except that the pretreatment antibody is added in comparison with the first embodiment. Therefore, in describing the seventh embodiment, the same reference numerals are assigned to the components common to those of the first embodiment, and the detailed description is omitted.

Referring to FIG. 15, the cartridge 1000 according to the seventh embodiment may include a first area 1011, a second area 1013, a third area 1015, and a preprocessed area 1019.

The first region 1011, the second region 1013, and the third region 1015 may be sequentially arranged along the first direction. The preprocessed region 1019 may be disposed between the first region 1011 and the second region 1013.

A test line 1040 may be located in the third region 1015. The test line 1040 may comprise a plurality of antibodies 1040.

A plurality of competitors 1050 may be introduced into the second region 1013. The plurality of competitors 1050 may include an antigen derivative 1051 and a marker 1053. The antigen derivative (1051) may include the competitor antigen (1055) and the cross linker (1057).

The specimen 1060 may be introduced into the first region 1011. The specimen 1060 may include a fluid 1061 and an antigen 1063. The antigen 1063 may include a high-density lipoprotein (HDL) antigen 1063a and an LDL (low-density lipoprotein) antigen 1063b. The HDL antigen 1063a may be in the form of an antigen and an antigen linked thereto. The LDL antigen 1063b may be in the form of an LDL and an antigen linked to each other.

A pretreatment material may be introduced into the pretreatment region 1019. The pretreatment material may be a substance capable of pretreating the specimen 1060. The pretreatment material may be a pretreatment antibody that specifically binds to a specific substance of the specimen 1060. The pretreatment material may be an LDL antibody 1100 that specifically binds to the LDL of the specimen 1060 as shown in the figure.

The LDL antibody 1100 may be provided in a fixed state in the pretreatment region 1019. The LDL antibody 1100 can specifically bind LDL of the specimen 1060. The LDL antibody 1100 may bind to the LDL antigen 1063b of the specimen 1060 and may not bind to the HDL antigen 1063a.

In the operation of the cartridge 1000 according to the seventh embodiment, the specimen 1060 may be introduced into the first region 1011 as shown in FIG.

The fluid 1061 may move in the first direction. The antigen 1063 can be moved in the first direction by movement of the fluid 1061. The antigen 1063 can reach the pretreatment region 1019. [ The LDL antigen 1063b of the antigen 1063 is coupled to the LDL antibody 1100 and the HDL antigen 1063a is coupled to the second region 1013 ).

The fluid 1061 moves to the second region 1013 to release the fixed competitor 1050 and the competitor 1050 can also be moved in the first direction by movement of the fluid 1061. [

The HDL antigen 1063a may reach the test line 1040 before the competitor 1050. [ The HDL antigen 1063a binds to the antibody 1041 and the plurality of competitors 1050 reaches the test line 1040 after the HDL antigen 1063a binds to the antibody 1041. [ An unbound antibody that is not bound to the HDL antigen 1063a may be associated with the plurality of competitors 1050. The competitor 1050 that can not bind to the antibody 1041 can reach the absorbent pad 1030.

When movement and reaction of the antigen 1063 and the competitor 1050 by the fluid 1061 are completed, the state shown in FIG. 16 is obtained.

The LDL antigen 1063b may be immobilized on the LDL antibody 1100 fixed on the development pad 1010. That is, the LDL antibody 1100 can bind to the LDL antigen 1063b. An HDL antigen 1063a or a competitor 1050 may be coupled onto the antibody 1041 immobilized on the test line 1040.

The diagnostic apparatus 100 may detect the presence and concentration of the HDL antigen 1063a of the specimen 1060 by measuring a signal of the test line 1040. When the antigen 1063 is S1P, the diagnostic device 100 can measure the S1P concentration bound to the HDL of the specimen 1060. [ In the case of S1P, since the diagnosis accuracy of S1P combined with HDL is higher than that of S1P combined with LDL, the diagnostic apparatus 100 can measure the S1P concentration bound to HDL of the specimen 1060, The risk of osteoporotic fracture can be diagnosed.

Although not shown in the drawing, the pretreatment material may be a dissolving substance that dissolves the specimen 1060. The cells in the specimen 1060 can be dissolved through the dissolution material. As a result, the diagnostic accuracy of the diagnostic device 100 can be improved.

Alternatively, the pretreatment material may be the bleaching material of the specimen 1060. The pretreatment material may be made of bleaching material to bleach the red component of plasma contained in the specimen 1060. As a result, the background effect occurring when the wavelength of the test line 1040 is measured by the measuring unit 130 of the diagnostic apparatus 100 can be reduced, and the diagnostic accuracy can be improved.

17 is a view showing a cartridge according to an eighth embodiment.

The cartridge according to the eighth embodiment is the same as the first embodiment except that the antigen is fixed and then the specimen is inserted to diagnose the presence or concentration of the specimen in a competitive manner. Therefore, in describing the cartridge according to the eighth embodiment, the same reference numerals are assigned to the components common to those of the first embodiment, and a detailed description thereof will be omitted.

Referring to FIG. 17, the cartridge 1000 according to the eighth embodiment may include a developing pad 1010 and an absorbing pad 1030.

The development pad 1010 may include a first region 1011, a second region 1013, and a third region 1015. The first region 1011, the second region 1013, and the third region 1015 may be sequentially arranged along the first direction. A test line 1040 may be located in the third region 1015. The test line 1040 may comprise a plurality of immobilized antigens 1210.

The fixed antigen 1210 may be an antigenic derivative. The immobilized antigen 1210 may comprise a material for immobilizing the antigen and the antigen on the deployment pad 1010.

The specimen 1060 may be introduced into the first region 1060. The specimen 1060 may include a fluid 1061 and a plurality of antigens 1063.

A plurality of sensing conductors 1220 may be introduced into the second region 1013. The sensing derivative 1220 may include the sensing antibody 1221 and the sensing marker 1223. The detection antibody 1221 may be combined with the detection marker 1223.

The sensing derivative 1220 can selectively bind to any one of the antigen 1063 and the fixing antigen 1210 of the specimen 1060. When the sensing derivative 1220 is coupled with the antigen 1063, the sensing derivative 1220 can not bind to the fixing antigen 1210 and when the sensing derivative 1220 is coupled with the fixing antigen 1210 The sensing derivative 1220 can not bind to the antigen 1063.

The detection antibody 1221 of the sensing derivative 1220 can selectively bind to any one of the antigen 1063 and the fixing antigen 1210 of the specimen 1060.

The detection marker 1223 may include a fluorescent material. The detection marker 1223 may include gold, silver, europium, or quantum dot. The detection markers 1223 can output light of a specific wavelength. The detection markers 1223 can receive light and output light of a specific wavelength.

Hereinafter, the operation of the cartridge 1000 according to the eighth embodiment will be described.

FIG. 18 is a view showing the movement of the sample and the sensing derivative at the first time point in the cartridge according to the eighth embodiment, and FIG. 19 is a graph showing the movement of the sample and the sensing derivative at the second time point in the cartridge according to the eighth embodiment. And FIG. 20 is a diagram showing the movement of the sample and the sensing derivative at the third time point in the cartridge according to the eighth embodiment.

The cartridge 1000 according to the eighth embodiment may include a development pad 1010 and an absorption pad 1030. [ The cartridge 1000 is provided with a fixed antigen 1210 fixed on a test line 104 as shown in FIG. 17, and a sensing derivative 1220 introduced therein. The sensing derivative 1220 is introduced into a second region 1013 and the fixed antigen 1210 is fixed in a third region 1015.

The specimen 1060 may be introduced into the first region 1011. The specimen 1060 may include the fluid 1061 and a plurality of antigens 1063.

Referring to FIG. 18, the specimen 1060 introduced into the first region 1011 can move in the first direction. The specimen 1060 introduced into the first region 1011 can move in the direction of the test line 1040.

The specimen 1060 may include a fluid 1061 and a plurality of antigens 1063. The fluid 1061 may move in a first direction. The plurality of antigens 1063 may move toward the test line 1040 by movement of the fluid 1061.

The sensing conductor 1220 fixed to the second region 1013 by the movement of the fluid 1061 can be released from the fixing. The sensing conductor 1220 can move in the first direction by the movement of the fluid 1061.

The sensing derivative 1220 and the plurality of antigens 1063 may meet in the second region 1013.

Referring to FIG. 19, the plurality of antigens 1063 and the sensing derivative 1220 may move from the second region 1013 to the third region 1015 by the fluid 1061. The plurality of antigens 1063 and the sensing derivative 1220 may be combined. The plurality of antigens 1063 may be respectively coupled to the sensing antibody 1221 of the sensing derivative 1220.

The plurality of antigens 1063 and the sensing derivative 1220 may move in a first direction while being coupled to each other. In addition, the sensing derivative 1220, which is not coupled to the antigen 1063, may also move in the first direction. The plurality of antigens 1063 and the sensing derivatives 1220 may reach the test line 1040.

Referring to FIG. 20, the plurality of antigens 1063 and the sensing derivative 1220 can be moved to the absorption pad 1030 by the fluid 1061.

The sensing derivative 1220 of the sensing derivative 1220 combined with the antigen 1063 may move to the absorption pad 1030. Since the sensing derivative 1220 coupled with the antigen 1063 of the sensing derivative 1220 does not bind to the fixing antigen 1210, the sensing derivative 1220 coupled with the antigen 1063 is electrically connected to the test line 1040 Even if it passes through the absorption pad 1030, it moves to the absorption pad 1030 without reacting with the fixed antigen 1210.

The sensing derivative 1220 that is not coupled to the antigen 1063 of the sensing derivative 1220 can be coupled to the immobilized antigen 1210 when passing through the test line 1040. The sensing antibody 1221 of the sensing derivative 1220 couples with the immobilized antigen 1210 and the sensing derivative 1220 of the sensing derivative 1220 that is not coupled to the antigen 1063 is electrically connected to the test line 1040, As shown in FIG.

The diagnostic apparatus 100 may measure the signal of the test line 1040 and calculate the presence of the antigen 1063 and the concentration of the antigen 1063 in the specimen 1060. The diagnostic apparatus 100 measures a signal of the sensing derivative 1220 fixed on the test line 1040 and determines whether the sample 1060 is in the presence of the antigen 1063 and the concentration of the antigen 1063 Can be calculated. The signal outputted from the detection marker 1223 of the sensing derivative 1220 fixed in the test line 1040 is measured to determine whether the sample 1060 is present in the presence of the antigen 1063 and the concentration of the antigen 1063 Can be calculated.

The number of the sensing derivatives 1220 introduced into the second region 1013 may correspond to the number of the fixed antigens 1210. If the number of the detection derivatives 1220 does not correspond to the number of the fixed antigens 1210, the diagnostic accuracy may be lowered.

For example, if the number of the sensing derivatives 1220 is significantly larger than the number of the fixed antigens 1210, even if the antigens 1063 and the sensing derivatives 1220 are combined, May be coupled to the sensing conductor 1220. Thus, the sensing derivative 1220 outputs the same signal regardless of the number and concentration of the antigens 1063 of the specimen 1060, so that the diagnostic accuracy of the diagnostic device 100 can not be guaranteed.

For example, if the number of the detection derivatives 1220 is significantly smaller than the number of the fixed antigens 1210, the range of the signal output from the test line 1040 is narrowed. That is, the deviation of the maximum number and the minimum number of the sensing conductors 1220 fixed to the test line 1040 is small, so that the diagnostic accuracy of the diagnostic device 100 can not be guaranteed.

Therefore, it is possible to improve the accuracy of diagnosis by the diagnostic device 100 by setting the number of the sensing derivatives 1220 introduced into the second region 1013 to correspond to the number of the fixed antigens 1210.

The number of the sensing conductors 1220 introduced into the second region 1013 is determined by the number of the sensing conductors 1220 that the sensing conductors 1220 reach the test line 1040, As shown in FIG. The number of the sensing conductors 1220 reaching the test line 1040 may be reduced to the number of the sensing conductors 1220 corresponding to the fixed antigens 1210, The accuracy of the diagnostic device 100 can be improved by setting the number of the sensing derivatives 1220 to be introduced into the second region 1013.

A region of the second region 1013 adjacent to the third region 1015 and a region of the third region 1015 adjacent to the second region 1013 The test line 1040 may have a lower development speed than the other areas. The region may have a lower development rate from the test line 1040 to the region adjacent to the absorbent pad 1030 in the third region 1015.

The reaction time between the antigen 1063 and the sensing derivative 1220 can be secured by setting the region at a lower development rate than the other regions. The speed variation between the antigen 1063 and the sensing derivative 1220 can be reduced by setting the region at a lower development rate than the other regions so that the distance between the antigen 1063 and the sensing electrode 1220 before reaching the test line 1040, So that the sensing derivative 1220 can be sufficiently reacted.

If the velocity deviation between the antigen 1063 and the sensing derivative 1220 is large, the antigen can not bind to the specimen derivative 1220 among the antigens 1063 contained in the specimen 1060, An antigen migrating to the absorption pad 1030 may be generated and the diagnostic accuracy may be lowered. In this case, the antigen 1063 moves at a high speed so that the sensing derivative 1220, which is not coupled to the antigen 1063, is fixed to the fixed antigen 1210 and can generate a signal, thereby reducing the diagnostic accuracy . Therefore, the development speed of the area can be made lower than other areas, thereby improving the diagnostic accuracy.

FIG. 21 is a view showing a cartridge according to the ninth embodiment, and FIG. 22 is a view showing a solution insertion of the cartridge according to the ninth embodiment.

The cartridge according to the ninth embodiment is the same as the cartridge according to the ninth embodiment, except that it further includes a solution reservoir. Therefore, in describing the cartridge according to the ninth embodiment, the same reference numerals are assigned to the same components as those in the first embodiment, and a detailed description thereof will be omitted.

Referring to FIG. 21, the cartridge 1000 according to the ninth embodiment may include a development pad 1010, an absorption pad 1030, and a solution storage portion 1300.

The development pad 1010 may include a first region 1011, a second region 1013, and a third region 1015. The first region 1011, the second region 1013, and the third region 1015 may be sequentially arranged along the first direction.

A test sample 1060 is introduced into the first region 1011 and a competitor 1050 is introduced into the second region 1013 and a test line 1040 is placed in the third region 1015. [ The test line 1040 may comprise a plurality of antibodies 1041.

The solution reservoir 1300 may be disposed between the first region 1011 and the second region 1013. The solution reservoir 1300 may store the solution 1310. The solution reservoir 1300 may be formed in a piston shape, for example. The solution reservoir 1300 may provide the solution 1310 to the deployment pad 1010. The solution reservoir 1300 may provide the solution 1310 between the first region 1011 and the second region 1013.

The solution reservoir 1300 may provide the solution 1310 to the development pad 1010 at an upper portion of the development pad 1010. The solution storage part 1300 may provide the solution 1310 to the development pad 1010 on the side surface of the development pad 1010.

The solution 1310 may be a material that can be absorbed by the development pad 1010. The solution 1310 may have a hydrogen ion concentration index to control the hydrogen ion concentration index of the development pad 1010; The hydrogen ion concentration index of the solution 1310 may vary depending on the type of the specimen 1060, the competitor 1050, and the antibody 1041 and the binding environment. The solution 1310 can be used to adjust the hydrogen ion concentration index of the deployment pad 1010 so that the reaction between the antigen 1063 and the antibody 1041 becomes active and the diagnostic accuracy can be improved.

In the operation of the cartridge 1000 according to the ninth embodiment, the specimen 1060 may be introduced into the first region 1011 as shown in FIG.

The fluid 1061 may move in the first direction. By the movement of the fluid 1061, the antigen 1063 can be moved in the first direction. After the antigen 1063 moves to at least the second region 1013, the solution storage portion 1300 may inject the solution 1310 into the development pad 1010. The solution storage portion 1300 may inject the solution 1310 between the first region 1011 and the second region 1013.

As shown in FIG. 22, the solution 1310 may be injected into the development pad 1010 to generate the restricted region 1320. The restriction region 1320 may be formed in an area including a region into which the solution 1310 is injected. The restriction region 1320 may restrict movement of the antigen 1061 of the first region 1011 to the second region 1013.

When the solution 1310 is introduced into the development pad 1010, the solution 1310 is absorbed by the development pad 1010, but the solution 1310, which exceeds the absorption capacity of the development pad 1010, The restriction region 1320 is formed in a part of the expansion pad 1010 and the movement of the substance existing on the upstream side of the restriction region 1320 can be restricted. That is, the movement of the antigen 1063 present in the first region 1011 is restricted. The antigen 1063 and the competitor 1050 located downstream of the restriction region 1320 caused by the movement of the fluid 1061 by the absorption pad 1030 are positioned downstream of the restriction region 1320, And is moved in the lateral direction. That is, the antigens 1063 and the competitor 1050 existing in the second region 1013 and the third region 1015 are moved in the first direction despite the introduction of the solution 1310. Further, the immobilization of the fixed competitor 1050 existing on the downstream side of the restriction region 1320 can be accelerated by the injection of the solution 1310. [

The diagnostic device 100 may control the injection timing of the solution 1310. There is an effect that the antigen 1063 moving in the direction of the test line 1040 can be quantified by controlling the injection timing of the solution 1310. The diagnostic apparatus 100 can control the solution 1310 from the solution reservoir 1300 to be injected into the deployment pad 1010 after a predetermined time elapses after the specimen 1060 is introduced. The same amount of the antigen 1063 is transferred to the test line 1040 in the different cartridges by limiting the injecting time of the solution 1310 to the diagnostic device 100 after a certain period of time since the introduction of the sample 1060 .

The solution 1310 has a hydrogen ion concentration index so that the reaction conditions of the antigen 1063, the competitor 1050 and the antibody 1041 on the downstream side of the restriction region 1320 can be changed. By setting the hydrogen ion concentration index of the solution 1310 to match the reaction conditions of the antibody 1041 and the antigen 1063 and the competitor 1050, the antibody 1041 and the antigen 1063 and the competitor 1050 ) Can be improved.

FIG. 23 is a view showing a cartridge according to the tenth embodiment, FIG. 24 is a view showing a cartridge into which the cleaning solution according to the tenth embodiment is inserted, and FIG. 25 is a view showing the cartridge after the cleaning solution according to the tenth embodiment Fig.

The cartridge according to the tenth embodiment is the same as the first embodiment except that the cleaning solution is injected in comparison with the first embodiment. Therefore, in describing the tenth embodiment, the same reference numerals are assigned to the same components as those of the first embodiment, and a detailed description thereof will be omitted.

Referring to FIG. 23, the cartridge 1000 according to the tenth embodiment may include a developing pad 1010, an absorbent pad 1030, and a cleaning container 1400.

The development pad 1010 may include a first region 1011, a second region 1013, and a third region 1015. The first region 1011, the second region 1013, and the third region 1015 may be sequentially arranged along the first direction.

A test sample 1060 is introduced into the first region 1011 and a competitor 1050 is introduced into the second region 1013 and a test line 1040 is placed in the third region 1015. [ The test line 1040 may comprise a plurality of antibodies 1041.

The cleaning vessel 1400 may be located above the deployment pad 1010. The cleaning vessel 1400 may be located above the third region 1015. The cleaning vessel 1400 may be located in an area adjacent to the test line 1040. The cleaning vessel 1400 may be located on the side of the deployment pad 1010.

The cleaning vessel 1400 may receive the cleaning liquid 1410. The cleaning vessel 1400 may be formed, for example, in a piston shape. The cleaning vessel 1400 may inject the cleaning liquid 1410 into the development pad 1010. The cleaning vessel 1400 may inject the cleaning solution 1410 into the third region 1015. The cleaning vessel 1400 may inject the cleaning solution 1410 into an area adjacent to the test line 1040.

The cleaning liquid 1410 may be a solution for cleaning the development pad 1010. The cleaning liquid 1410 removes the material remaining on the development pad 1010, thereby reducing the background of the diagnostic device 100 when measuring a signal of the test line 1040. In addition, the cleaning liquid 1410 may be a substance that suppresses nonspecific reaction in the development pad 1010. The cleaning liquid 1410 can suppress the nonspecific reaction in the development pad 1010 and improve the diagnostic accuracy.

Referring to the operation of the cartridge 1000 according to the tenth embodiment, the specimen 1060 may be introduced into the first region 1011 as shown in FIG.

The fluid 1061 may move in a first direction. By the movement of the fluid 1061, the plurality of antigens 1063 can be moved in the first direction. By movement of the fluid 1061, the plurality of competitors 1050 can also be moved in the first direction.

The plurality of antigens 1063 move to the third region 1015 through the first region 1011 and the second region 1013 by the movement of the fluid 1061, Moves from the second region 1013 to the third region 1015 by the movement of the fluid 1061.

At least one antigen of the plurality of antigens 1063 may reach the test line 1040. At least one antigen of the plurality of antigens 1063 may reach the test line 1040 earlier than the competitor 1050. Preferably, the competitor 1050 may reach the test line 1040 after all of the plurality of antigens 1063 have reached the test line 1040.

The antigen 1063 and the competitor 1050 that are not coupled to the antibody 1041 may be absorbed into the absorption pad 1030 by movement of the fluid 1061 as shown in FIG. A portion of the antigen 1063 and competitor 1050 may remain in the deployment pad 1010. Or a portion of the antigen 1063 and the competitor 1050 may be non-specifically associated with the antibody 1041 immobilized on the test line 1040 and may not migrate to the absorbent pad 1030. Or a background signal may be generated in the measurement due to the plasma component of the specimen 1060 as the blood component.

The cleaning vessel 1400 may inject the cleaning solution 1410 into the area around the test line 1040.

The washing solution 1410 may be introduced into the development pad 1010 after any antigen 1063 of the plurality of antigens 1063 meets the test line 1040. The cleaning liquid 1410 may be introduced into the development pad 1010 after all of the plurality of antigens 10630 reach the test line 1040. More preferably, A plurality of competitors 1050 may all be introduced into the deployment pad 1010 after reaching the test line 1040. The cleaning solution 1410 may be introduced into the test line 1040 after all of the immune reactions have been completed in the test line 1040 Can be injected.

When the cleaning liquid 1410 is supplied, the cleaning liquid 1410 can move in the first direction by the absorption force of the absorption pad 1030. The antigen 1063 and / or the competitor 1050 remaining on the development pad 1010 by the movement of the washing solution 1410 in the first direction are moved toward the absorption pad 1030 by the washing solution 1410 Can be moved.

The absorbing pad 1030 is separated from the absorbing pad 1030 by the non-specific reaction inhibiting force of the washing liquid 1410, and the absorbing pad 1030 is separated from the absorbing pad 1030, Direction. Alternatively, the cleaning solution 1410 may reduce the background effect by improving the plasma component remaining in the development pad 1010.

When the movement of the cleaning solution 1410 on the development pad 1010 is completed, the competitor 1050 and unreacted antigen are all moved to the absorption pad 1030 as shown in FIG.

The absorption pad 1030 may be a pad having an absorption capacity capable of absorbing both the fluid 1061 and the cleaning fluid 1410. The absorbing capacity of the absorbing pad 1030 to absorb both the fluid 1061 and the washing liquid 1410 can increase the reaction speed and improve the accuracy.

26 is a view showing a cartridge according to the eleventh embodiment.

The cartridge according to the eleventh embodiment is the same as the cartridge according to the tenth embodiment except that it has two absorption pads. Therefore, in describing the eleventh embodiment, the same reference numerals are assigned to the same components as those of the tenth embodiment, and a detailed description thereof is omitted.

Referring to Fig. 26, the cartridge 1000 according to the eleventh embodiment may include a developing pad 1010, a first absorbing pad 1030, a second absorbing pad 1430, and a cleaning container 1400. Fig.

The development pad 1010 may include a first region 1011, a second region 1013, and a third region 1015. The first region 1011, the second region 1013, and the third region 1015 may be sequentially arranged along the first direction.

A test sample 1060 is introduced into the first region 1011 and a competitor 1050 is introduced into the second region 1013 and a test line 1040 is placed in the third region 1015. [ The test line 1040 may comprise a plurality of antibodies 1041. The cleaning vessel 1400 may be located above the deployment pad 1010. The cleaning vessel 1400 may receive the cleaning liquid 1410.

The first absorbent pad 1030 may contact the deployment pad 1010. The second absorbent pad 1430 may contact the first absorbent pad 1030. A part of the first absorbent pad 1030 may be overlapped with the development pad 1010. A part of the second absorption pad 1430 may be formed to overlap with the first absorption pad 1030.

The first absorbent pad 1030 and the second absorbent pad 1430 can absorb moisture. The first absorption pad 1030 and the second absorption pad 1430 may have absorption capacities, respectively. The first absorbing pad 1030 and the second absorbing pad 1430 may have different absorbing forces. The absorption force of the second absorption pad 1430 may be greater than the absorption force of the first absorption pad 1030. The first absorbent pad 1030 can absorb moisture transferred from the development pad 1010. The second absorption pad 1430 can absorb moisture absorbed by the first absorption pad 1030.

Referring to the operation of the cartridge 1000 according to the eleventh embodiment, the specimen 1060 may be introduced into the first region 1011 as shown in FIG.

The fluid 1061 may move in a first direction. By the movement of the fluid 1061, the plurality of antigens 1063 can be moved in the first direction. By movement of the fluid 1061, the plurality of competitors 1050 can also be moved in the first direction. The movement of the fluid 1061 may be caused by absorption of the first absorption pad 1030 and the second absorption pad 1430.

The plurality of antigens 1063 move to the third region 1015 through the first region 1011 and the second region 1013 by the movement of the fluid 1061, Moves from the second region 1013 to the third region 1015 by the movement of the fluid 1061.

At least one antigen of the plurality of antigens 1063 may reach the test line 1040. At least one antigen of the plurality of antigens 1063 may reach the test line 1040 earlier than the competitor 1050. Preferably, the competitor 1050 may reach the test line 1040 after all of the plurality of antigens 1063 have reached the test line 1040.

The fluid 1061 may be absorbed by the first absorbent pad 1030. The fluid 1061 absorbed by the first absorbent pad 1030 can be absorbed by the second absorbent pad 1430. That is, the fluid 1061 absorbed by the first absorbent pad 1030 can be transmitted to the second absorbent pad 1430. The absorption capacity of the first absorption pad 1030 can be raised by the second absorption pad 1430.

The cleaning vessel 1400 may introduce the cleaning liquid 1410 into the development pad 1010. Movement of the cleaning liquid 1410 may also be induced from the first absorbent pad 1030 and the second absorbent pad 1430. The first absorbent pad 1030 may absorb the cleaning liquid 1410. The second absorbent pad 1430 may also absorb the absorbed cleaning fluid 1410 in the first absorbent pad 1030.

The cartridge of the eleventh embodiment has the effect of adding the second absorbent pad 1430 to the first absorbent pad 1030 to perform the cleaning process under a stable structure. In addition, the moving speed of the fluid 1061 and the washing liquid 1410 is increased by the first absorbing pad 1030 and the second absorbing pad 1430, thereby reducing the overall reaction speed.

27 is a view showing a cartridge according to a twelfth embodiment. FIG. 28 is a view showing the cartridge before the cleaning solution according to the twelfth embodiment is inserted, and FIG. 29 is a view showing the cartridge after the cleaning solution according to the twelfth embodiment is inserted.

The cartridge according to the twelfth embodiment is the same as the cartridge according to the eleventh embodiment except that the two absorbent pads are provided in an overlapped manner at the top and bottom. Therefore, in describing the twelfth embodiment, the same reference numerals are assigned to the same components as those of the eleventh embodiment, and a detailed description thereof will be omitted.

Referring to Fig. 27, the cartridge 1000 according to the twelfth embodiment may include a development pad 1010, a first absorption pad 1030, a second absorption pad 1440, and a cleaning vessel 1400. Fig.

The development pad 1010 may include a first region 1011, a second region 1013, and a third region 1015. The first region 1011, the second region 1013, and the third region 1015 may be sequentially arranged along the first direction.

A test sample 1060 is introduced into the first region 1011 and a competitor 1050 is introduced into the second region 1013 and a test line 1040 is placed in the third region 1015. [ The test line 1040 may comprise a plurality of antibodies 1041. The cleaning vessel 1400 may be located above the deployment pad 1010. The cleaning vessel 1400 may receive the cleaning liquid 1410.

The first absorbent pad 1030 may contact the deployment pad 1010. The second absorbing pad 1440 may contact the first absorbing pad 1030. A part of the first absorbent pad 1030 may be overlapped with the development pad 1010. The second absorbent pad 1440 may be positioned on the first absorbent pad 1030. The second absorbent pad 1440 may include a protrusion 1443 projecting in the upstream direction on the first absorbent pad 1030. The protrusion 1443 may protrude toward the test line 1040 with respect to the first absorbent pad 1030.

Although not shown, a blocking pad may be positioned between the first absorbent pad 1030 and the second absorbent pad 1440. The blocking pad may prevent moisture transfer between the first absorbent pad 1030 and the second absorbent pad 1440 between the first absorbent pad 1030 and the second absorbent pad 1440 .

The first absorbent pad 1030 and the second absorbent pad 1440 can absorb moisture. The first absorption pad 1030 and the second absorption pad 1440 may have absorption capacities, respectively. The first absorbing pad 1030 and the second absorbing pad 1440 may have different absorbing powers. The absorption force of the second absorption pad 1440 may be greater than the absorption force of the first absorption pad 1030.

Referring to the operation of the cartridge 1000 according to the twelfth embodiment, the specimen 1060 may be introduced into the first region 1011 as shown in FIG.

The fluid 1061 may move in a first direction. By the movement of the fluid 1061, the plurality of antigens 1063 can be moved in the first direction. By movement of the fluid 1061, the plurality of competitors 1050 can also be moved in the first direction. The movement of the fluid 1061 may be caused by the absorption of the first absorbent pad 1030.

The plurality of antigens 1063 move to the third region 1015 through the first region 1011 and the second region 1013 by the movement of the fluid 1061, Moves from the second region 1013 to the third region 1015 by the movement of the fluid 1061.

At least one antigen of the plurality of antigens 1063 may reach the test line 1040. At least one antigen of the plurality of antigens 1063 may reach the test line 1040 earlier than the competitor 1050. Preferably, the competitor 1050 may reach the test line 1040 after all of the plurality of antigens 1063 have reached the test line 1040.

The fluid 1061 may be absorbed by the first absorbent pad 1030. The reaction of the antigen 1063, the competitor 1050 and the antibody 1041 may be terminated as shown in FIG. Even if the reaction of the antigen 1063, the competitor 1050 and the antibody 1041 is terminated, the antigen 1063 and the competitor 1050, which have not migrated to the first absorption pad 1030, ).

The projection 1443 of the second absorbent pad 1440 may contact the deployment pad 1010 by an external force when the cleaning liquid 1410 is inserted or before the cleaning liquid 1410 is inserted as shown in FIG. The diagnostic device 100 may control the mechanical configuration to contact the protrusion 1443 with the deployment pad 1010. The diagnostic device 100 may contact the deployment pad 1010 after the fluid has reached the first absorbent pad 1030 or the immune system of the antigen 1063, the competitor 1050 and the antibody 1041 The protrusion 1443 of the second absorbent pad 1440 can be brought into contact with the deployment pad 1010. When the second absorbent pad 1440 and the development pad 1010 are in contact with each other, A path can be created from the deployment pad 1010 to the second absorption pad 1440.

The cleaning vessel 1400 may introduce the cleaning liquid 1410 into the development pad 1010. The first absorption pad 1030 may absorb a portion of the cleaning liquid 1410. [ The second absorbent pad 1440 may absorb the washing liquid 1410 from the deployment pad 1010 through the protrusions 1443.

The cartridge of the twelfth embodiment is effective in that the second absorption pad 1430 is added to the first absorption pad 1030 to perform the cleaning process under a stable structure. The second absorbent pad 1440 may be in contact with the deployment pad 1010 to absorb the absorbent 1410 while the second absorbent pad 1440 does not absorb moisture from the first absorbent pad 1030, The cleaning liquid 1410 can be absorbed by the inherent absorption power of the cleaning liquid 1410, thereby increasing the cleaning effect.

FIG. 30 is a view showing a cartridge according to a thirteenth embodiment, FIG. 31 is a view showing a cartridge according to a thirteenth embodiment before the cleaning liquid is introduced, and FIG. 32 is a cross- Fig.

The cartridge according to the thirteenth embodiment is different from the tenth embodiment except that the cleaning solution is injected at the side of the deployment pad and the second absorption pad is disposed at the other side of the deployment pad and the test line is formed diagonally same. Therefore, in describing the thirteenth embodiment, the same reference numerals are assigned to the same components as those of the tenth embodiment, and a detailed description thereof will be omitted.

Referring to FIG. 30, a cartridge 1000 according to a thirteenth embodiment may include a development pad 1010, a first absorption pad 1030, a second absorption pad 1510, and a cleaning vessel 1400.

The development pad 1010 may include a first region 1011, a second region 1013, and a third region 1015. The first region 1011, the second region 1013, and the third region 1015 may be sequentially arranged along the first direction.

The deployment pad 1010 may have a first side 1016 and a second side 1018 in a second direction. The first side surface 1016 and the second side surface 1018 may be opposite to each other in the second direction.

The first absorbent pad 1030 may be disposed in contact with the downstream side of the deployment pad 1010.

The second absorbent pad 1510 may be disposed in contact with the first side 1016.

A test sample 1060 is introduced into the first region 1011 and a competitor 1050 is introduced into the second region 1013 and a test line 1040 is placed in the third region 1015. [ The test line 1040 may comprise a plurality of antibodies 1041.

The test line 1540 may extend diagonally. The test line 1540 may have both ends. The test line 1540 may have a first end 1543 and a second end 1545.

The first end 1543 of the test line 1540 may be adjacent to the first side 1016 of the deployment pad 1010. The first end 1543 of the test line 1540 may contact the first side 1016 of the deployment pad 1010. The second end 1545 of the test line 1540 may be adjacent to the second side 1018 of the deployment pad 1010. The second end 1545 of the test line 1540 may contact the second side surface 1018 of the deployment pad 1010.

Both ends of the test line 1540 are located on the upstream side of the first absorbent pad 1030 and the second absorbent pad 1510. That is, the distance between the first end 1543 of the test line 1540 and the first region 1011 is shorter than the distance between the second absorbent pad 1510 and the first region 1011. The distance between the second end 1545 of the test line 1540 and the first region 1011 is shorter than the distance between the first absorbent pad 1030 and the first region 1011.

Both ends of the test line 1540 are positioned on the upstream side of the first absorbent pad 1030 and the second absorbent pad 1510 to be absorbed by the first absorbent pad 1030 and the second absorbent pad 1510 All fluids 1061 and cleaning fluids 1410 may be fluids 1061 and cleaning fluids 1410 that have passed through the test line 1540.

The test line 1540 may comprise a plurality of antibodies 1541. The plurality of antibodies 1541 may be formed along the test line 1540. That is, the plurality of antibodies 1541 may be arranged in a diagonal direction of the development pad 1010, which is a rectangular shape when viewed from above.

The cleaning vessel 1400 may be positioned on the side of the deployment pad 1010. The cleaning vessel 1400 may be located in an area adjacent the second side 1018 of the deployment pad 1010. The cleaning liquid 1410 from the cleaning vessel 1400 may be introduced in the second direction.

Referring to the operation of the cartridge 1000 according to the thirteenth embodiment, the specimen 1060 may be introduced into the first region 1011 as shown in FIG.

The fluid 1061 may move in a first direction. By the movement of the fluid 1061, the plurality of antigens 1063 can be moved in the first direction. By movement of the fluid 1061, the plurality of competitors 1050 can also be moved in the first direction. The movement of the fluid 1061 may be caused by the absorbency of the first absorbing pad 1030 and the second absorbing pad 1510.

The plurality of antigens 1063 move to the third region 1015 through the first region 1011 and the second region 1013 by the movement of the fluid 1061, Moves from the second region 1013 to the third region 1015 by the movement of the fluid 1061.

At least one antigen of the plurality of antigens 1063 may reach the test line 1540. At least one antigen of the plurality of antigens 1063 may first reach the test line 1540 rather than the competitor 1050. Preferably, the competitor 1050 may reach the test line 1540 after all of the plurality of antigens 1063 have reached the test line 1540.

The fluid 1061 may be absorbed by at least one of the first absorption pad 1030 and the second absorption pad 1510. The fluid 1061 may be absorbed by the first absorbent pad 1030 and the second absorbent pad 1510. The reaction of the antigen 1063, the competitor 1050 and the antibody 1041 may be terminated as shown in FIG. Even if the reaction of the antigen 1063, the competitor 1050 and the antibody 1041 is terminated, the development pad 1010 can not move to the first absorption pad 1030 or the second absorption pad 1510 Antigen 1063 and competitor 1050 remain.

As shown in FIG. 32, the cleaning vessel 1400 can introduce the cleaning liquid 1410 into the development pad 1010. The cleaning liquid 1410 may be absorbed by at least one of the first absorption pad 1030 and the second absorption pad 1510. The cleaning liquid 1410 may be absorbed by the first absorbing pad 1030 and the second absorbing pad 1510.

The cartridge of the thirteenth embodiment can inject the cleaning liquid 1410 from the side while the first absorbent pad 1030 and the second absorbent pad 1510 are in contact with the development pad 1010. As a result, the absorbing power of the first absorbing pad 1030 and the second absorbing pad 1510 is assured to absorb the washing liquid 1410 smoothly and the test line 1540 is formed diagonally so that the fluid 1061 and the washing liquid (1410) are all passed through the test line (1540), so that the efficiency of the immune reaction and washing is increased.

33 is a view showing a cartridge according to the fourteenth embodiment.

The fourteenth embodiment is the same as the thirteenth embodiment except that the interface of the area of the development pad is configured to be parallel to the test line as compared with the thirteenth embodiment. Therefore, in describing the fourteenth embodiment, the same reference numerals are assigned to the components common to those of the thirteenth embodiment, and a detailed description thereof will be omitted.

Referring to FIG. 33, the cartridge 1000 according to the fourteenth embodiment may include a development pad 1010, a first absorption pad 1030, a second absorption pad 1610, and a cleaning container 1400.

The development pad 1010 may include a first region 1011, a second region 1013, and a third region 1015. The first region 1011, the second region 1013, and the third region 1015 may be sequentially arranged along the first direction.

The first absorbent pad 1030 may be disposed in contact with the downstream side of the deployment pad 1010.

The second absorbent pad 1610 may be disposed in contact with the first side 1016.

The first absorbing pad 1030 and the second absorbing pad 1610 may be disposed in contact with each other. The first absorption pad 1030 and the second absorption pad 1610 may be integrally formed.

A test sample 1060 is introduced into the first region 1011 and a competitor 1050 is introduced into the second region 1013 and a test line 1040 is placed in the third region 1015. [ The test line 1040 may comprise a plurality of antibodies 1041.

The test line 1540 may extend diagonally.

The boundary between the first region 1011 and the second region 1013 may be parallel to the test line 1040. The boundary between the second region 1013 and the third region 1015 may be parallel to the test line 1040. The boundary between the development pad 1010 and the first absorption pad 1030 may be parallel to the test line 1040. A boundary between the first region 1011 and the second region 1013, a boundary between the second region 1013 and the third region 1015, a boundary between the development pad 1010 and the first absorption pad 1030 The absorption force acting in the first direction may be the same in all directions. Therefore, there is an effect that a more accurate diagnosis can be performed.

Although not shown in further detail, the specimen 1060 may also be provided in parallel with the test line 1540. When the specimen 1060 is provided in an elliptical shape, the long axis of the elliptical shape may be provided parallel to the test line 1540.

Although not shown, a housing that accommodates the deployment pad 1010, the first absorbent pad 1030, the second absorbent pad 1610, and the cleaning container 1400 may be provided, When the specimen 1060 is introduced into the development pad 1010, the shape of the hole passing through the housing is designed to be an elliptic shape having a long axis parallel to the test line 1540, 1060) may be introduced. When the specimen 1060 is provided in a shape corresponding to the test line 1540 as described above, the diagnostic accuracy can be further improved.

While the present invention has been described with reference to exemplary embodiments, it is to be understood that the invention is not limited to the disclosed exemplary embodiments, but, on the contrary, It will be apparent to those skilled in the art that changes or modifications may fall within the scope of the appended claims.

100: Diagnostic device
110:
130:
1000: Cartridge

Claims (21)

A deployment pad in which a plurality of antigens and fluids move in a first direction;
A first absorbent pad in contact with the deployment pad to absorb the fluid to cause the fluid to move in a first direction on the deployment pad;
A second absorbing pad located on a first side of the deployment pad in a second direction and in contact with the deployment pad; And
And a cleaning vessel located in a region adjacent to a second side in the second direction of the deployment pad, the cleaning vessel receiving a cleaning liquid,
A test line is formed on the development pad,
The fluid is absorbed into the first absorbing pad and / or the second absorbing pad through the test line,
The washing liquid is absorbed into at least one of the first absorbing pad and the second absorbing pad through the test line,
Wherein all of the fluid and wash fluid absorbed by the first or second absorbent pad is the fluid and wash fluid past the test line.
The method according to claim 1,
Wherein the development pad comprises a first region and a second region,
Wherein a sample containing a plurality of antigens and fluids is introduced into the first region,
The test line is located in the second area,
Wherein the first end of the test line is adjacent to the first side and the second end of the test line is adjacent to the second side.
3. The method of claim 2,
Wherein the distance between the first end of the test line and the first region is shorter than the distance between the second absorbent pad and the first region.
The method of claim 3,
Wherein the distance between the second end of the test line and the first region is shorter than the distance between the first absorbent pad and the first region.
The method according to claim 1,
Said test line extending diagonally on said deployment pad.
The method according to claim 1,
Wherein the wash liquid is introduced into the development pad after the antigen of any one of the plurality of antigens meets the test line.
delete The method according to claim 1,
Wherein the first absorbent pad and the second absorbent pad are integrally formed.
3. The method of claim 2,
Wherein the boundary between the first region and the second region is parallel to the test line.
6. The method of claim 5,
Wherein a boundary between the development pad and the first absorption pad is parallel to the test line.
3. The method of claim 2,
And a third region located between the first region and the second region,
A competitor is introduced into the third area,
And the boundary between the third region and the second region is parallel to the test line.
The method according to claim 1,
Said deployment pad. A first absorbent pad. A second absorbent pad, and a housing for receiving the cleaning container,
Wherein a hollow is formed in the housing to allow a specimen from the outside to be introduced into the deployment pad,
Wherein the long axis of the hollow is parallel to the test line.
delete delete delete delete delete delete delete delete delete

Images